[{"role": "model", "parts": [{"text": "You are a specialized assistant, and given a publication you can identify which are the mentioned datasets the study is based on. You will retrieve this information and create a summary of the publication datasets for non-specialists. You must output a JSON array of objects, where each object has the following keys: 'dataset_identifier', 'repository_reference'."}]}, {"role": "model", "parts": [{"text": "Dataset Identifiers are any alphanumeric strings (they can also contain punctuation marks) that uniquely identify and/or provide access to a dataset\n.Here are some examples for reference:\n\n[\n'dataset_identifier'=> 'EGAS00001000925', 'repository_reference'=> 'https://ega-archive.org/datasets/EGAS00001000925',\n 'dataset_identifier'=> 'GSE69091', 'repository_reference'=> 'https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69091',\n  'dataset_identifier'=> 'PRJNA306801', 'repository_reference'=> 'https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA306801',\n  'dataset_identifier'=> 'phs003416.v1.p1', 'repository_reference'=> 'dbGaP',\n  'dataset_identifier'=> 'PXD049309', 'repository_reference'=> 'https://www.ebi.ac.uk/pride/archive/projects/PXD049309',\n  'dataset_identifier'=> 'IPX0004230000', 'repository_reference'=> 'http://www.iprox.org',\n  'dataset_identifier'=> 'MSV000092944', 'repository_reference'=> 'https://massive.ucsd.edu/',\n  'dataset_identifier'=> 'n/a', 'repository_reference'=> 'https://data.broadinstitute.org/ccle_legacy_data/mRNA_expression/'\n]"}]}, {"role": "user", "parts": [{"text": "Given the following webpage HTML:\n<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4836692/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1371/journal.pgen.1005895\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/pgen.1005895.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4836692/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"PLOS Genetics logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-plosgen.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to PLOS Genetics\" href=\"https://doi.org/10.1371/journal.pgen.1005895\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to PLOS Genetics\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> PLoS Genet </button> </div> . 2016 Apr 19;12(4):e1005895. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pgen.1005895\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1371/journal.pgen.1005895 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22PLoS%20Genet%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22PLoS%20Genet%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22PLoS%20Genet%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22PLoS%20Genet%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> Genomic Landscape Survey Identifies <em> SRSF1 </em> as a Key Oncodriver in Small Cell Lung Cancer </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Liyan Jiang </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Liyan Jiang </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Liyan Jiang </span> </a> </div> </div> <sup> 1, </sup> <sup> # </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jiaqi Huang </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> Jiaqi Huang </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jiaqi Huang </span> </a> </div> </div> <sup> 2, </sup> <sup> # </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Higgs%20BW%22%5BAuthor%5D\"> <span class=\"name western\"> Brandon W Higgs </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Brandon W Higgs </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Higgs%20BW%22%5BAuthor%5D\"> <span class=\"name western\"> Brandon W Higgs </span> </a> </div> </div> <sup> 2, </sup> <sup> # </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhibin Hu </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Zhibin Hu </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhibin Hu </span> </a> </div> </div> <sup> 3, </sup> <sup> # </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xiao%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhan Xiao </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Zhan Xiao </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xiao%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhan Xiao </span> </a> </div> </div> <sup> 2, </sup> <sup> # </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xin Yao </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Xin Yao </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xin Yao </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Conley%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sarah Conley </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> Sarah Conley </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Conley%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sarah Conley </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Haihong Zhong </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> Haihong Zhong </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Haihong Zhong </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zheng Liu </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> Zheng Liu </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zheng Liu </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id10\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Brohawn%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Philip Brohawn </span> </a> <div hidden=\"hidden\" id=\"id10\"> <h3> <span class=\"name western\"> Philip Brohawn </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Brohawn%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Philip Brohawn </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id11\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dong Shen </span> </a> <div hidden=\"hidden\" id=\"id11\"> <h3> <span class=\"name western\"> Dong Shen </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dong Shen </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id12\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Song Wu </span> </a> <div hidden=\"hidden\" id=\"id12\"> <h3> <span class=\"name western\"> Song Wu </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Song Wu </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id13\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ge%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xiaoxiao Ge </span> </a> <div hidden=\"hidden\" id=\"id13\"> <h3> <span class=\"name western\"> Xiaoxiao Ge </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ge%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xiaoxiao Ge </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id14\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yue Jiang </span> </a> <div hidden=\"hidden\" id=\"id14\"> <h3> <span class=\"name western\"> Yue Jiang </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yue Jiang </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id15\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yizhuo Zhao </span> </a> <div hidden=\"hidden\" id=\"id15\"> <h3> <span class=\"name western\"> Yizhuo Zhao </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yizhuo Zhao </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id16\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lou%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yuqing Lou </span> </a> <div hidden=\"hidden\" id=\"id16\"> <h3> <span class=\"name western\"> Yuqing Lou </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lou%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yuqing Lou </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id17\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Morehouse%20C%22%5BAuthor%5D\"> <span class=\"name western\"> Chris Morehouse </span> </a> <div hidden=\"hidden\" id=\"id17\"> <h3> <span class=\"name western\"> Chris Morehouse </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Morehouse%20C%22%5BAuthor%5D\"> <span class=\"name western\"> Chris Morehouse </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id18\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wei Zhu </span> </a> <div hidden=\"hidden\" id=\"id18\"> <h3> <span class=\"name western\"> Wei Zhu </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wei Zhu </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id19\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sebastian%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yinong Sebastian </span> </a> <div hidden=\"hidden\" id=\"id19\"> <h3> <span class=\"name western\"> Yinong Sebastian </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sebastian%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yinong Sebastian </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id20\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Czapiga%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Meggan Czapiga </span> </a> <div hidden=\"hidden\" id=\"id20\"> <h3> <span class=\"name western\"> Meggan Czapiga </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Czapiga%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Meggan Czapiga </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id21\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Oganesyan%20V%22%5BAuthor%5D\"> <span class=\"name western\"> Vaheh Oganesyan </span> </a> <div hidden=\"hidden\" id=\"id21\"> <h3> <span class=\"name western\"> Vaheh Oganesyan </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Oganesyan%20V%22%5BAuthor%5D\"> <span class=\"name western\"> Vaheh Oganesyan </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id22\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Haihua Fu </span> </a> <div hidden=\"hidden\" id=\"id22\"> <h3> <span class=\"name western\"> Haihua Fu </span> </h3> <div class=\"p\"> <sup> 4 </sup> Asia &amp; Emerging Markets iMed, AstraZeneca R&amp;D, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Haihua Fu </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id23\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Niu%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yanjie Niu </span> </a> <div hidden=\"hidden\" id=\"id23\"> <h3> <span class=\"name western\"> Yanjie Niu </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Niu%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yanjie Niu </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id24\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wei Zhang </span> </a> <div hidden=\"hidden\" id=\"id24\"> <h3> <span class=\"name western\"> Wei Zhang </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wei Zhang </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id25\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Streicher%20K%22%5BAuthor%5D\"> <span class=\"name western\"> Katie Streicher </span> </a> <div hidden=\"hidden\" id=\"id25\"> <h3> <span class=\"name western\"> Katie Streicher </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Streicher%20K%22%5BAuthor%5D\"> <span class=\"name western\"> Katie Streicher </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id26\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Tice%20D%22%5BAuthor%5D\"> <span class=\"name western\"> David Tice </span> </a> <div hidden=\"hidden\" id=\"id26\"> <h3> <span class=\"name western\"> David Tice </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Tice%20D%22%5BAuthor%5D\"> <span class=\"name western\"> David Tice </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id27\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Heng Zhao </span> </a> <div hidden=\"hidden\" id=\"id27\"> <h3> <span class=\"name western\"> Heng Zhao </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Heng Zhao </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id28\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Meng Zhu </span> </a> <div hidden=\"hidden\" id=\"id28\"> <h3> <span class=\"name western\"> Meng Zhu </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Meng Zhu </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id29\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Lin Xu </span> </a> <div hidden=\"hidden\" id=\"id29\"> <h3> <span class=\"name western\"> Lin Xu </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Lin Xu </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id30\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbst%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Ronald Herbst </span> </a> <div hidden=\"hidden\" id=\"id30\"> <h3> <span class=\"name western\"> Ronald Herbst </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbst%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Ronald Herbst </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id31\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Su%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xinying Su </span> </a> <div hidden=\"hidden\" id=\"id31\"> <h3> <span class=\"name western\"> Xinying Su </span> </h3> <div class=\"p\"> <sup> 4 </sup> Asia &amp; Emerging Markets iMed, AstraZeneca R&amp;D, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Su%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xinying Su </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id32\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gu%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yi Gu </span> </a> <div hidden=\"hidden\" id=\"id32\"> <h3> <span class=\"name western\"> Yi Gu </span> </h3> <div class=\"p\"> <sup> 4 </sup> Asia &amp; Emerging Markets iMed, AstraZeneca R&amp;D, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gu%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yi Gu </span> </a> </div> </div> <sup> 4 </sup> , <a aria-describedby=\"id33\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Shyoung Li </span> </a> <div hidden=\"hidden\" id=\"id33\"> <h3> <span class=\"name western\"> Shyoung Li </span> </h3> <div class=\"p\"> <sup> 5 </sup> Beijing Genomics Institute, Shenzhen GuangDong, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Shyoung Li </span> </a> </div> </div> <sup> 5 </sup> , <a aria-describedby=\"id34\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Lihua Huang </span> </a> <div hidden=\"hidden\" id=\"id34\"> <h3> <span class=\"name western\"> Lihua Huang </span> </h3> <div class=\"p\"> <sup> 5 </sup> Beijing Genomics Institute, Shenzhen GuangDong, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Lihua Huang </span> </a> </div> </div> <sup> 5 </sup> , <a aria-describedby=\"id35\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gu%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jianren Gu </span> </a> <div hidden=\"hidden\" id=\"id35\"> <h3> <span class=\"name western\"> Jianren Gu </span> </h3> <div class=\"p\"> <sup> 6 </sup> Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gu%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jianren Gu </span> </a> </div> </div> <sup> 6 </sup> , <a aria-describedby=\"id36\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Baohui Han </span> </a> <div hidden=\"hidden\" id=\"id36\"> <h3> <span class=\"name western\"> Baohui Han </span> </h3> <div class=\"p\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Baohui Han </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id37\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jallal%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Bahija Jallal </span> </a> <div hidden=\"hidden\" id=\"id37\"> <h3> <span class=\"name western\"> Bahija Jallal </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Jallal%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Bahija Jallal </span> </a> </div> </div> <sup> 2 </sup> , <a aria-describedby=\"id38\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Hongbing Shen </span> </a> <div hidden=\"hidden\" id=\"id38\"> <h3> <span class=\"name western\"> Hongbing Shen </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20H%22%5BAuthor%5D\"> <span class=\"name western\"> Hongbing Shen </span> </a> </div> </div> <sup> 3, </sup> <sup> * </sup> , <a aria-describedby=\"id39\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yihong Yao </span> </a> <div hidden=\"hidden\" id=\"id39\"> <h3> <span class=\"name western\"> Yihong Yao </span> </h3> <div class=\"p\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yihong Yao </span> </a> </div> </div> <sup> 2, </sup> <sup> * </sup> </div> <div class=\"cg p\"> Editor: <span class=\"name western\"> Peter Hammerman </span> <sup> 7 </sup> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"aff001\"> <sup> 1 </sup> Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China </div> <div id=\"aff002\"> <sup> 2 </sup> Medimmune, Gaithersburg, Maryland, United States of America </div> <div id=\"aff003\"> <sup> 3 </sup> Department of Epidemiology and Biostatistics, Collaborative Innovation Center of Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, China </div> <div id=\"aff004\"> <sup> 4 </sup> Asia &amp; Emerging Markets iMed, AstraZeneca R&amp;D, Shanghai, China </div> <div id=\"aff005\"> <sup> 5 </sup> Beijing Genomics Institute, Shenzhen GuangDong, China </div> <div id=\"aff006\"> <sup> 6 </sup> Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China </div> <div id=\"edit1\"> <sup> 7 </sup> Dana Farber Cancer Institute, UNITED STATES </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"coi001\"> <p> JH, BWH, ZX, SC, YX, SC, BZ, CS, DS, SW, KS, LZ, ZH,TC, WZ, YS, MC, VO, RH, BJ, and YY are employees of Medimmune. XS, YU, HF are employees of AstraZeneca. They own AstraZeneca stock. </p> </div> <div class=\"fn\" id=\"contrib001\"> <p> Conceived and designed the experiments: LJ JH BWH ZX ZH HS YY HZ. Performed the experiments: XY SC HZ ZL PB DS XG YJ YZ YL CM WZ YS MC VO HF YN WZ HZ MZ. Analyzed the data: LJ JH BWH ZX ZH HS YY HZ XY SC HZ ZL PB DS SW KS XG YJ YZ YL CM WZ YS MC VO HF YN WZ HZ MZ DT LX RH XS YG SL LH JG BH BJ. Contributed reagents/materials/analysis tools: LJ SH YL XG YJ MC. Wrote the paper: LJ JH BWH ZX ZH HS YY HZ LZ SD. </p> </div> <div class=\"fn\" id=\"cor001\"> <sup> \u2709 </sup> <p class=\"display-inline\"> * E-mail: <span> hbshen@njmu.edu.cn </span> (HS); <span> oliver_67@yahoo.com </span> (YY) </p> </div> <div class=\"fn\" id=\"_eqcntrb93pmc__\"> <sup> # </sup> <p class=\"display-inline\"> Contributed equally. </p> </div> </div> <h4 class=\"font-secondary\"> Roles </h4> <div class=\"p\"> <strong class=\"contrib\"> <span class=\"name western\"> Peter Hammerman </span> </strong> : <span class=\"role\"> Editor </span> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Received 2015 Oct 19; Accepted 2016 Feb 3; Collection date 2016 Apr. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div> \u00a9 2016 Jiang et al </div> <p> This is an open access article distributed under the terms of the <a class=\"usa-link usa-link--external\" href=\"http://creativecommons.org/licenses/by/4.0/\" rel=\"noopener noreferrer\" target=\"_blank\"> Creative Commons Attribution License </a> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. </p> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC4836692 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27093186/\"> 27093186 </a> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"abstract1\"> <h2> <a class=\"usa-anchor\" id=\"abstract1-anchor\"> </a> Abstract </h2> <p> Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however, much still remains unknown, particularly in the Asian patient population. Here we conducted whole exome sequencing (WES) and transcriptomic sequencing of primary tumors from 99 Chinese SCLC patients. Dysregulation of tumor suppressor genes <em> TP53 </em> and <em> RB1 </em> was observed in 82% and 62% of SCLC patients, respectively, and more than half of the SCLC patients (62%) harbored <em> TP53 </em> and <em> RB1 </em> mutation and/or copy number loss. Additionally, Serine/Arginine Splicing Factor 1 ( <em> SRSF1 </em> ) DNA copy number gain and mRNA over-expression was strongly associated with poor survival using both discovery and validation patient cohorts. Functional studies <em> in vitro </em> and <em> in vivo </em> demonstrate that SRSF1 is important for tumorigenicity of SCLC and may play a key role in DNA repair and chemo-sensitivity. These results strongly support SRSF1 as a prognostic biomarker in SCLC and provide a rationale for personalized therapy in SCLC. </p> </section> <section class=\"abstract\" id=\"abstract2\"> <h2> <a class=\"usa-anchor\" id=\"abstract2-anchor\"> </a> Author Summary </h2> <p> SCLC patients are initially highly chemo-sensitive with response rates of greater than 80% in both limited and extensive diseases, but suffer uniform disease recurrence or progression in a very short period of time. In the absence of well-defined genomic biomarkers and insights into the resistance mechanism, many targeted treatments have yielded negative results in the last decade Using integrated next generation sequencing (NGS) technology in combination with a high quality surgical sample set with comprehensive clinical annotation, our study not only identified novel recurrent genetic alterations in genes such as CDH10 and DNA repair pathways which may influence outcomes in SCLC patients, but also discovered the expression of SRSF1, an RNA-splicing factor which can both regulate key oncogenic and survival pathways such as BCL2, and play a critical role in patient survival. </p> </section> <section id=\"sec001\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec001-anchor\"> </a> Introduction </h2> <p> Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of lung cancer worldwide with more than 180,000 cases per year [ <a aria-describedby=\"pgen.1005895.ref001\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref001\"> 1 </a> ]. It is an aggressive neuroendocrine malignancy with a unique natural history of a short doubling time, high growth fraction, and early development of widespread metastases [ <a aria-describedby=\"pgen.1005895.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref002\"> 2 </a> ]. Most patients are very sensitive to thoracic radiotherapy and platinum drugs such as cisplatin and carboplatin, but suffer disease recurrence or progression in a very short period of time following initial treatment [ <a aria-describedby=\"pgen.1005895.ref001\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref001\"> 1 </a> ]. Currently, for recurrent or progressive SCLC, the only drug approved in the United States and Europe is topotecan, a topoisomerase 1 ( <em> Top1 </em> ) inhibitor which provides some benefit, though the five year survival rate of SCLC has remained unchanged at~5% for the last four decades [ <a aria-describedby=\"pgen.1005895.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref002\"> 2 </a> ]. </p> <p> To improve patient outcomes in SCLC, it is critical to understand the key genetic alterations that contribute to the specific disease phenotypes and their utility for potential therapeutic targets. However, systematic genetics and genomics analyses of large cohorts of SCLC patients remains a challenge, primarily because SCLC usually presents as extensive disease upon diagnosis and hence is rarely treated surgically, thus causing a lack of suitable tumor specimens for comprehensive analysis. To date, these types of extensive genome-wide molecular analyses have been performed on relatively small patient cohorts, which provide utility restricted to the disease population sampled [ <a aria-describedby=\"pgen.1005895.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref003\"> 3 </a> , <a aria-describedby=\"pgen.1005895.ref004\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref004\"> 4 </a> , <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. Within these studies, among genes recurrently affected by genomic alterations in SCLC, <em> TP53 </em> , <em> RB1 </em> , as well as the amplification of <em> MYC </em> family members and <em> SOX2 </em> have been identified. However, the molecular factors related to chemo-sensitivity or resistance remain unknown. Additionally, clinical outcome such as survival in relation to genetic alterations remains unreported, particularly in the SCLC Chinese patient population. </p> <p> Here, we conducted the first comprehensive genetic landscape survey of Chinese SCLC patients with whole exome sequencing (WES) and transcriptomic sequencing of primary tumors from 99 SCLC patients with detailed clinical history and survival data. Our study not only identified novel recurrent genetic alterations such as <em> CDH10 </em> and DNA repair pathways which may influence outcomes in SCLC patients, but also revealed <em> SRSF1 </em> , an RNA-splicing factor which can form complexes with TP53 and Top1, and plays a critical role in SCLC patient survival. </p> </section> <section id=\"sec002\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec002-anchor\"> </a> Results </h2> <section id=\"sec003\"> <h3 class=\"pmc_sec_title\"> Recurrent mutations in SCLC Chinese patients </h3> <p> WES of 25 normal [normal adjacent tissue (NAT) or blood] and matched tumor pairs, and 74 tumors only (no normal tissue) from Chinese SCLC patients revealed 32,566 somatic non-silent single nucleotide variants (SNVs) or insertion/deletions (indels), an average of 329 per patient and non-silent/silent ratio of 2.11. The patient summary is described in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.t001\"> Table 1 </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s012\"> S1 Table </a> </strong> . The most frequent transition and transversion changes were G&gt;A and G&gt;T, respectively, consistent with a previous report in SCLC [ <a aria-describedby=\"pgen.1005895.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref002\"> 2 </a> ]. Genes harboring the most recurrent somatic SNVs or indels were <em> TP53 </em> (82%), <em> RB1 </em> (47%), <em> CSMD3 </em> (47%), <em> NOTCH1 </em> (18%) and <em> NOTCH3 </em> (15%) ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s013\"> S2 Table </a> </strong> ). <em> TP53 </em> and <em> RB1 </em> have been reported previously as the most recurrent genes harboring nonsilent somatic SNVs in SCLC [ <a aria-describedby=\"pgen.1005895.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref002\"> 2 </a> , <a aria-describedby=\"pgen.1005895.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref003\"> 3 </a> , <a aria-describedby=\"pgen.1005895.ref004\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref004\"> 4 </a> ]. Oncogenic gain-of-function mutations in <em> NOTCH1 </em> commonly occur in human T-cell acute lymphocytic leukemia (T-ALL) and B-cell chronic lymphocytic leukemia [ <a aria-describedby=\"pgen.1005895.ref006\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref006\"> 6 </a> , <a aria-describedby=\"pgen.1005895.ref007\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref007\"> 7 </a> , <a aria-describedby=\"pgen.1005895.ref008\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref008\"> 8 </a> ]. Loss-of-function mutations in Notch receptors have been recently reported to likely play a tumor suppressor role in lung squamous cell carcinoma and SCLC patients [ <a aria-describedby=\"pgen.1005895.ref009\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref009\"> 9 </a> , <a aria-describedby=\"pgen.1005895.ref010\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref010\"> 10 </a> ]. Additionally, the concordance between the top 100 genes harboring the most recurrent nonsilent somatic SNVs or indels in this study and a recent WES study of Asian SCLC patients (Japanese; n = 51) was 62% ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s013\"> S2 Table </a> </strong> ), with strong consistency of recurrence prevalence in <em> TP53 </em> (82% vs. 80%), <em> RB1 </em> (47% vs. 39%), and <em> CSMD3 </em> (47% vs. 37%), among other genes, between the two studies [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. </p> <section class=\"tw xbox font-sm\" id=\"pgen.1005895.t001\"> <h4 class=\"obj_head\"> Table 1. Summary of clinical features of SCLC patients. </h4> <div class=\"tbl-box p\" tabindex=\"0\"> <table class=\"content\" frame=\"hsides\" rules=\"groups\"> <colgroup span=\"1\"> <col align=\"left\" span=\"1\" valign=\"middle\"/> <col align=\"left\" span=\"1\" valign=\"middle\"/> </colgroup> <thead> <tr> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> Patients </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> n = 99 (Chinese) </th> </tr> <tr> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> </th> <th align=\"left\" colspan=\"1\" rowspan=\"1\"> No. (%) </th> </tr> </thead> <tbody> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Gender </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Male </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 86(87%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Female </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 13(13%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Age (years) </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Mean </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 57.92 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Median </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 57 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Range </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 36\u201378 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Outcome </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Follow-up (months) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 1\u201366.2 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Median follow-up(months) </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 21.3 </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Death </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 43(43%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Alive </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 52(53%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Lost to Follow-Up </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 3(3%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Stage </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> I </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 18(18%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> II </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 15(15%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> III </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 62(63%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> IV </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 4(4%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Cigarette Smoking </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Smoker </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 75(76%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Non-smoker </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 24(24%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Precure Neochemotherapy </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Treated </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 8(9%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Na\u00efve </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 91(91%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Specimens </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tumor sample with matched normal </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 25(25%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Tumor sample only </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 74(75%) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> <strong> Sequencing summary </strong> </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> Exon seq </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 99(100) </td> </tr> <tr> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> RNA seq </td> <td align=\"left\" colspan=\"1\" rowspan=\"1\"> 50(50%) </td> </tr> </tbody> </table> </div> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"table/pgen.1005895.t001/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> </section> <p> To further narrow down the most disease-relevant mutated genes, we first generated a list of genes harboring the most recurrent and significant nonsilent somatic mutations (identified with two independent algorithms). Then this list was intersected with two independent lists of significantly mutated genes in SCLC generated by both Peifer et al [ <a aria-describedby=\"pgen.1005895.ref004\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref004\"> 4 </a> ] and Umemura et al [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ] studies. Aside from <em> TP53 </em> and <em> RB1 </em> , neural cell transmembrane genes <em> TMEM132D </em> , <em> NCAM2 </em> , and <em> CDH10 </em> were shared in all three independent studies ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s014\"> S3 Table </a> </strong> ).The mutation rates of <em> TMEM132D </em> , <em> NCAM2 </em> , <em> CDH10 </em> in our Chinese patient cohort were 14%, 13% and 12%, respectively. </p> <p> To evaluate the impact of these mutations in these three genes on patient outcomes, we used a Cox proportion hazard (PH) regression model to correlate the mutation status with survival. The patients were split into two groups: those harboring at least one nonsilent somatic mutation and those without. Among these three genes, patients with mutations in <em> CDH10 </em> , a cadherin which is predominantly expressed in brain [ <a aria-describedby=\"pgen.1005895.ref011\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref011\"> 11 </a> ], displayed a significant association with poor survival, after adjusting for age, gender, tumor stage, and chemotherapy status (p = 0.0127). Twelve of 99 patient harbored <em> CDH10 </em> mutations, mostly located in the cadherin domain with high confidence protein affecting predictions (i.e. SIFT) ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g001\"> Fig 1 </a> </strong> ). </p> <figure class=\"fig xbox font-sm\" id=\"pgen.1005895.g001\"> <h4 class=\"obj_head\"> Fig 1. Mutations in <em> CDH10 </em> associate with poor survival in Chinese SCLC patients. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4836692_pgen.1005895.g001.jpg\" target=\"_blank\"> <img alt=\"Fig 1\" class=\"graphic zoom-in\" height=\"597\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cdd/4836692/34a1c01833fb/pgen.1005895.g001.jpg\" width=\"735\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pgen.1005895.g001/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> a) Schematic representation of amino acid consequences from mutations identified in SCLC patients in human CDH10 protein b) Kaplan-Meier (KM) curves comparing survival between patients harboring at least one nonsilent mutation in <em> CDH10 </em> (n = 12) and those not (n = 84).p* = log-rank test; p = Cox PH regression model; HR = hazard ratio </p> </figcaption> </figure> <p> To better understand the genetic basis of chemo sensitivity and resistance in SCLC, we systematically surveyed SNVs and indels in all known DNA repair genes [ <a aria-describedby=\"pgen.1005895.ref012\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref012\"> 12 </a> ]. Eighty-seven percent (87%) of patients harbored \u22651 nonsilent somatic SNV in a DNA repair gene besides <em> TP53 </em> ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s015\"> S4 Table </a> </strong> ); similarly, within a Japanese SCLC study cohort in a previous study, 69% of patients were identified by the same criterion [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. The patient prevalence of nonsilent somatic SNVs in genes classified as mismatch repair (MMR), nucleotide excision repair (NER), homologous recombination, or DNA polymerase were 22%, 30%, 26% and 35%, respectively. Twelve percent of patients harbored nonsilent somatic SNVs in DNA polymerase genes that are involved in DNA replication in NER and MMR ( <em> POLD1 </em> and <em> POLE </em> , [ <a aria-describedby=\"pgen.1005895.ref013\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref013\"> 13 </a> ]). <em> POD1 </em> , <em> POLG </em> and <em> POLQ </em> were most recurrently mutated among the 15 DNA polymerase genes. These somatic SNVs cause protein truncations and amino acid changes in the polymerase, exonuclease, and helicase domains ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g002\"> Fig 2A\u20132C </a> </strong> ). Fanconi anemia pathway genes were most recurrent with prevalence of 36%. Within this specific pathway, multiple genes involved in DNA inter-strand crosslink repair such as <em> FANCM </em> (7%) and <em> BRIP1 </em> / <em> FANCJ </em> (7%) were among the most mutated ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g002\"> Fig 2D </a> </strong> ). Finally, 29% of patients harbored nonsilent somatic SNVs in genes that affect sensitivity of mammalian cells to topoisomerase inhibitors, in addition to <em> TP53 </em> [ <a aria-describedby=\"pgen.1005895.ref014\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref014\"> 14 </a> ]. </p> <figure class=\"fig xbox font-sm\" id=\"pgen.1005895.g002\"> <h4 class=\"obj_head\"> Fig 2. Top mutated DNA polymerases and mutation prevalence in Fanconi anemia pathway genes in SCLC. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4836692_pgen.1005895.g002.jpg\" target=\"_blank\"> <img alt=\"Fig 2\" class=\"graphic zoom-in\" height=\"944\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cdd/4836692/d0d73f696b86/pgen.1005895.g002.jpg\" width=\"795\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pgen.1005895.g002/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> ) Schematic representation of amino acid changes in human POLG, POLD1, POLQ proteins; <strong> b </strong> ) the amino acid alterations in human POLG catalytic domain. Mutations were mapped onto the structure of human POLG using PDB Id entry 3IKM as template [ <a aria-describedby=\"pgen.1005895.ref006\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref006\"> 6 </a> ]. <strong> c </strong> ) Relevant amino acid alterations in POLD1. Mutations in human POLD1 gene were mapped onto structure of the yeast DNA polymerase subunit \u03b4 using PDB entry 3IAY Orange colored ribbon represents exonuclease domain, blue colored ribbon corresponds to polymerase domain, and the green ribbon represents the N-terminal portion of the protein [ <a aria-describedby=\"pgen.1005895.ref027\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref027\"> 27 </a> ]. The mutations in both structures are shown in red spheres. <strong> d </strong> ) Mutation prevalence in Fanconi anemia pathway genes. </p> </figcaption> </figure> </section> <section id=\"sec004\"> <h3 class=\"pmc_sec_title\"> Recurrent somatic copy number variants SCLC Chinese patients </h3> <p> Somatic copy number variants (CNVs) were identified from exome-sequencing data. Our results confirmed key oncogenic genes with recurrent CN gains/amplifications that were previously reported in SCLC [ <a aria-describedby=\"pgen.1005895.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref003\"> 3 </a> , <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> , <a aria-describedby=\"pgen.1005895.ref015\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref015\"> 15 </a> , <a aria-describedby=\"pgen.1005895.ref016\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref016\"> 16 </a> , <a aria-describedby=\"pgen.1005895.ref017\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref017\"> 17 </a> ], including <em> MYC </em> (8%), <em> KIT </em> (16%), and <em> SOX2 </em> (67%). Significant copy number gains or amplifications were observed across a cluster on chromosome 3q26-29 [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ] ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s016\"> S5 Table </a> </strong> ). Genes with CN losses previously reported in SCLC [ <a aria-describedby=\"pgen.1005895.ref002\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref002\"> 2 </a> , <a aria-describedby=\"pgen.1005895.ref004\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref004\"> 4 </a> , <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ] include <em> RB1 </em> (34%), <em> RASSF1 </em> (57%), <em> FHIT </em> (54%), <em> KIF2A </em> (16%), and <em> PTEN </em> (13%). A long segment along chromosome 3p22 was also detected to have significant CN loss. Recurrence rates of these genes affected by CNVs were comparable to those reported previously [ <a aria-describedby=\"pgen.1005895.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref003\"> 3 </a> , <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. In addition, we found recurrent gains of <em> SRSF1 </em> (50%) as well as concordant over-expression of mRNA for those patients with gains (p = 0.005; two-tailed two-sided Welch\u2019s t-test; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3A </a> </strong> ). Among these 96 Chinese patients, 28% had both CN gain and mRNA over-expression of <em> SRSF1 </em> ; in an independent cohort of 25 Caucasian SCLC patients (commercially purchased specimens\u2013see <a class=\"usa-link\" href=\"#sec010\"> Methods </a> ), we identified 32% with the same result. Further, <em> SRSF1 </em> CN gain was determined to be 30% (8/27 SCLC patients) in a re-analysis of the available WES data published from a previous Caucasian SCLC patient cohort\u2013a result very similar between both Caucasian SCLC cohorts [ <a aria-describedby=\"pgen.1005895.ref003\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref003\"> 3 </a> ]. CN gains/amplifications or losses and somatic SNVs for relevant genes are summarized in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s001\"> S1 Fig </a> </strong> . </p> <figure class=\"fig xbox font-sm\" id=\"pgen.1005895.g003\"> <h4 class=\"obj_head\"> Fig 3. <em> SRSF1 </em> CN gain and mRNA expression correlates with survival. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4836692_pgen.1005895.g003.jpg\" target=\"_blank\"> <img alt=\"Fig 3\" class=\"graphic zoom-in\" height=\"477\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cdd/4836692/cfb0ed0584fd/pgen.1005895.g003.jpg\" width=\"775\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pgen.1005895.g003/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> A: The time-to-event analysis schema with available patient specimens. In the time-to-event analyses, 96 Chinese primary SCLC patients with clinical outcome were divided into training and test cohorts according to the availabilities of matched normal, RNAseq and survival outcome information. The training set includes 22 patients with each patient having tumor and normal WES data and survival outcome. The test set includes 74 patient tumors only. Each patient has WES data from tumor and survival outcome. Among those patients, 48 patients have WES, RNAseq data, and survival outcome. <strong> b </strong> ) <em> SRSF1 </em> mRNA expression in CN gain group and no CN gain group (p = Welch\u2019s t-test). <strong> c </strong> ) Kaplan-Meier (KM) curves comparing survival between <em> SRSF1 </em> low and high mRNA expression groups (n = 48). Similarly, KM curves used to evaluate the difference of survival between different <em> SRSF1 </em> CN statuses in <strong> d) </strong> discovery set (n = 22), <strong> e </strong> ) validation set (n = 74), and <strong> f </strong> ) combination of discovery set and validation set (n = 96). p* = log-rank test; p = Cox PH regression model; HR = hazard ratio. </p> </figcaption> </figure> <p> <em> SRSF1 </em> CN status was evaluated by FISH assay (N = 34). Using a FISH criterion described in the <strong> Methods </strong> for deviations from disomy [ <a aria-describedby=\"pgen.1005895.ref018\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref018\"> 18 </a> ], the sensitivity and specificity were 47% and 71% respectively (positive and negative predictive values of 57% and 62%, respectively). This is comparable to a previous study\u2019s concordance reported between FISH and sequencing using much greater sequencing depth (843X) detecting an EML4-ALK fusion in lung cancer [ <a aria-describedby=\"pgen.1005895.ref019\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref019\"> 19 </a> ]. Further, a clinical study detecting ALK fusions in lung cancer reported a positive predictive value between sequencing and FISH as 68% (19/28) among diagnostic characterized patients, and only 46% (6/13) when reduced to those patients with clinical outcomes (11/13 were sequencing positive and partial responders to crizotinib) [ <a aria-describedby=\"pgen.1005895.ref020\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref020\"> 20 </a> ]. These studies support both the lack of sensitivity in FISH assays compared to sequencing for detecting variants and comparability in concordance between these two assays in this study and two previous studies, both of which were detecting a much larger genetic variant ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s017\"> S6 Table </a> ; <a class=\"usa-link\" href=\"#pgen.1005895.s002\"> S2 Fig </a> </strong> ). </p> </section> <section id=\"sec005\"> <h3 class=\"pmc_sec_title\"> <em> SRSF1 </em> CN gain and mRNA over-expression predicts poor survival in Chinese SCLC patients </h3> <p> For patients with both survival and WES data (N = 96), genes within CN gain or loss regions were correlated with survival. The cohorts were separated into a discovery set (patients with tumors/matched normal; N = 22) and a validation set (patients with tumors only; N = 74). Kaplan-Meier analyses were conducted between patients with or without CN gains in the discovery cohort first (see <a class=\"usa-link\" href=\"#sec010\"> Methods </a> ). Then this gene list was reduced to those with log-rank p&lt;0.05 in the validation cohort. For the remaining genes, patients with both RNASeq and survival data were interrogated (N = 48) and <em> SRSF1 </em> was the only gene that correlated between both CN gain and mRNA over-expression at a p&lt;0.05 (log-rank p = 0.008; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3B </a> </strong> ) as well as between over-expression and survival using a Cox proportion hazard (PH) regression model adjusting for age, gender, tumor stage, and chemotherapy status (p = 0.047; HR = 2.7; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3C </a> </strong> ). Patients with <em> SRSF1 </em> mRNA over-expression or CN gain demonstrated significantly worse survival. The discovery (log-rank test p = 0.062), validation (log-rank test p = 0.03), and combined patient cohort (Cox PH p = 0.012; HR = 2.1; log-rank test p = 0.005) analyses are provided in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3D\u20133F </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s018\"> S7 Table </a> </strong> CN gains in <em> SRSF1 </em> from The Cancer Genome Atlas (TCGA) were interrogated for correlation with survival ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s003\"> S3 Fig </a> </strong> to evaluate the specificity of <em> SRSF1 </em> CN gains associating with survival in other cancer indications. We used a threshold of at least 3 patients for a particular cancer indication harboring a CN gain in <em> SRSF1 </em> to minimize biases in sample groups for survival analysis. Among cancer indications in TCGA with \u22653 patients harboring CN gains in <em> SRSF1 </em> (BRCA, KIRP, SARC, SKCM, and UCEC), uterine corpus endometrial carcinoma (UCEC) was the only indication with a correlation between <em> SRSF1 </em> CN gain and poor survival (log-rank test p = 0.003), though the patient number with a CN gain group was highly unbalanced compared to those without (n = 8 vs. n = 437, respectively), likely driving the low p-value. This result demonstrates how this CN gain in <em> SRSF1 </em> is specific to SCLC. </p> </section> <section id=\"sec006\"> <h3 class=\"pmc_sec_title\"> <em> SRSF1 </em> is a key mediator of growth and survival in <em> SRSF1 </em> high-expressing SCLC </h3> <p> We next evaluated SRSF1 as a potential tumor driver in SCLC. We first screened <em> SRSF1 </em> DNA CNs in 13 SCLC cell lines using TaqMan assays. Five of thirteen had <em> SRSF1 </em> CN&gt; = 3: Four including NCI-H82 had 3 copies, and DMS114 had 4 copies. These cell lines also expressed high levels of <em> SRSF1 </em> protein ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s004\"> S4 Fig </a> </strong> ). <em> SRSF1 </em> siRNA was transfected into DMS114, and the growth effect of <em> SRSF1 </em> ablation in two dimensional cell culture either alone or in conjunction with a sub-lethal dose of cisplatin or topotecan (two of the most common standard of care treatments in SCLC), was evaluated ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g004\"> Fig 4A </a> </strong> ). SRSF1 knockdown alone caused a 35% decrease in the proliferation rate. Treatment with a low dose of cisplatin or topotecan only induced a modest decrease of cell growth. However, combination with <em> SRSF1 </em> siRNA significantly enhanced the overall growth inhibition effect. </p> <figure class=\"fig xbox font-sm\" id=\"pgen.1005895.g004\"> <h4 class=\"obj_head\"> Fig 4. SRSF1 is required for tumorigenecity of SCLC. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4836692_pgen.1005895.g004.jpg\" target=\"_blank\"> <img alt=\"Fig 4\" class=\"graphic zoom-in\" height=\"374\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cdd/4836692/7336e406e7a5/pgen.1005895.g004.jpg\" width=\"737\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pgen.1005895.g004/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> ( <strong> a </strong> ) and ( <strong> b </strong> ): DMS114 cells were transfected with non-targeting control or SRSF1-directed siRNAs for 48 hrs, then treated with cisplatin (2.5ug/ml) or topotecan (2.5ug/ml) for 24 hrs. Cell growth ( <strong> a </strong> ) and Caspase-3/7 activities ( <strong> b </strong> ) were assessed and normalized against non-targeting ctrl siRNA-transfected cells as 100% control. ( <strong> c </strong> ): DMS114 cells were transfected with non-targeting and SRSF1 siRNAs for 48 hrs and then seeded in sphere forming media and allowed to grow for 4 days. Phase-contrast images of the sphere formation under each condition were captured and viable cell mass quantitated by CTG assay. ( <strong> d </strong> ): Reconstitution of SRSF1 expression using a siRNA-resistant Flag-tagged SRSF1 expression construct was carried out in SRSF1 siRNA transfected cells. Impact on sphere growth rate was assessed by CTG assay, and successful SRSF1 protein re-expression was confirmed using either anti-SRSF1 antibody or anti-Flag antibody. ( <strong> e </strong> ) DMS114 cells transfected with non-targeting control siRNA or SRSF1 siRNA were implanted into immunocompromised mice and tumor formation rates were monitored and measured as described in Materials and Methods. </p> </figcaption> </figure> <p> SRSF1 has also been shown to regulate the BCL2 pathway by alternative splicing of BIM, which results in a protein lacking pro-apoptotic activity [ <a aria-describedby=\"pgen.1005895.ref021\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref021\"> 21 </a> , <a aria-describedby=\"pgen.1005895.ref022\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref022\"> 22 </a> ]. In this study, we see that <em> SRSF1 </em> gene expression is positively correlated with BIM (r = 0.58, p&lt;0.0001) and <em> SRSF1 </em> CN gain or amplification also shows concordantly high expression of BIM ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s005\"> S5 Fig </a> </strong> ). Furthermore, we performed caspase-3/7 assays on similarly treated cells ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g004\"> Fig 4B </a> </strong> ) to evaluate the synergistic effect between SRSF1 knockdown and standard chemotherapy. <em> SRSF1 </em> siRNA alone induced modest but statistically significant caspase-3 activation, similar to cisplatin treatment alone. The combination of the two produced a substantially higher caspase induction. A similar trend was revealed with topotecan. Comparable results were also obtained in other SCLC models ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s004\"> S4 Fig </a> </strong> ). </p> <p> The effect of <em> SRSF1 </em> knockdown on SCLC cells when grown as 3D spheroids was evaluated next. Cells transfected with non-targeting siRNA produced large and well-organized spheroids; in contrast, cells transfected with <em> SRSF1 </em> siRNA did not form well-organized structures but mainly existed as single cells with poor viability ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g004\"> Fig 4C </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s006\"> S6B Fig </a> </strong> ). Results were confirmed by colony formation assays ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s006\"> S6D Fig </a> </strong> ). The effect of <em> SRSF1 </em> siRNA is mediated by specific target loss as demonstrated by a reconstitution study with a siRNA-resistant Flag-tagged expression construct which efficiently rescued the spheroid growth in the presence of the <em> SRSF1 </em> siRNA ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g004\"> Fig 4D </a> </strong> ). A similar rescue effect was also achieved in NCI-H82 cells ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s006\"> S6C Fig </a> </strong> ). </p> </section> <section id=\"sec007\"> <h3 class=\"pmc_sec_title\"> <em> SRSF1 </em> is required for in vivo tumorigenicity of SCLC </h3> <p> A tumor formation study was conducted using siRNA-transfected DMS114 and SHP-77 cells. Equal numbers of viable transfected cells were injected in immunocompromised mice and tumor growth was monitored for up to three weeks. <em> SRSF1 </em> knockdown completely suppressed the tumor growth in both SCLC models ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g004\"> Fig 4E </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s007\"> S7A Fig </a> </strong> ). </p> </section> <section id=\"sec008\"> <h3 class=\"pmc_sec_title\"> <em> SRSF1 </em> silencing triggers DNA-damage and suppresses <em> PI3K/AKT </em> and <em> MEK/ERK </em> pathways </h3> <p> DNA-damage induction as a potential effect of <em> SRSF1 </em> knockdown based on our DNA-repair analysis was assessed. Inductions of p-H2AX and Chk2, established markers of DNA-strand breaks and DNA-repair response [ <a aria-describedby=\"pgen.1005895.ref023\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref023\"> 23 </a> , <a aria-describedby=\"pgen.1005895.ref024\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref024\"> 24 </a> ], were consistently observed upon SRSF1 abrogation in DMS114 and SHP-77 ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g005\"> Fig 5A </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s007\"> S7B Fig </a> </strong> ), and increased phosphorylations were observed when we combined <em> SRSF1 </em> siRNA transfection and treatment with cisplatin or topotecan. </p> <figure class=\"fig xbox font-sm\" id=\"pgen.1005895.g005\"> <h4 class=\"obj_head\"> Fig 5. Mechanism of action for SRSF1 in SCLC. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4836692_pgen.1005895.g005.jpg\" target=\"_blank\"> <img alt=\"Fig 5\" class=\"graphic zoom-in\" height=\"452\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cdd/4836692/435830d1b3f3/pgen.1005895.g005.jpg\" width=\"707\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/pgen.1005895.g005/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> ) SRSF1 prevents DNA-damage. DMS114 cells were transfected with control or SRSF1 siRNA and then treated with topotecan or Cisplatin for the indicated times. SRSF1, phosphor-H2AX and phosphor-Chk2 were probed with their corresponding antibodies. <strong> b </strong> ) <strong> c </strong> ) SRSF1 mediates the activation of AKT and ERK pathways. DMS114 cells transfected with ctrl or SRSF1 siRNAs were lysed and applied to the phospho-kinase array as detailed in Materials and Methods. The dot blot result was further confirmed by western blot in both DMS114 and NCI-H1048 cells. </p> </figcaption> </figure> <p> To better understand the role of <em> SRSF1 </em> CN gain on downstream pathways in SCLC, we performed differential gene expression analysis between <em> SRSF1 </em> CN gain and <em> SRSF1 </em> CN neutral patients. A total of 861 genes were identified to be significantly expressed between these patient cohorts. Pathway analysis revealed that PIK3CA and MAPK3 were two of the top activated master regulators, which suggests that <em> SRSF1 </em> CN gain regulates PI3K/Akt and MAPK pathway activity with certain causality ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s023\"> S12 Table </a> </strong> ). Therefore, we investigated the impact of SRSF1 loss on both PI3K/Akt and Ras/Raf MAPK kinase signaling pathways in SCLC cells through phospho-kinase array profiling ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g005\"> Fig 5B </a> </strong> ). Control siRNA-transfected DMS114 displayed strong phospho-AKT and ERK signals, which were abrogated by <em> SRSF1 </em> siRNA. Western blot confirmed this in both DMS114 and NCI-H1048 cells ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g005\"> Fig 5C </a> </strong> ). This demonstrated that SRSF1 promotes SCLC growth and survival by sustaining PI3K/AKT and MEK/ERK pathways, two of the most well-established oncogenic pathways. </p> </section> </section> <section id=\"sec009\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec009-anchor\"> </a> Discussion </h2> <p> Our study represents the first comprehensive genetic landscape survey of Chinese SCLC patients with detailed clinical history, revealing key recurrent genetic alterations associated with patients\u2019 outcomes. </p> <p> Mutations identified in previous SCLC genomic studies shared little consensus for significantly mutated genes other than <em> TP53 </em> and <em> RB1 </em> . However, by leveraging our data with these previous SCLC studies, we were able to identify three additional common significantly mutated genes <em> (TMEM132D </em> , <em> NCAM2 </em> , and <em> CDH10 </em> ) with over 10% prevalence in SCLC. Interestingly, all three genes encode transmembrane proteins involved in neural cell adhesion. This finding will need to be further evaluated for the impact on neuroendocrine association in SCLC. </p> <p> Cadherins (CDHs) are important in maintenance of cell adhesion and polarity, alterations of which contribute to tumorigenesis. Recurrent mutations in <em> CDH10 </em> have recently been reported in <em> EGFR/KRAS/ALK </em> mutation-negative lung adenocarcinoma in never-smokers [ <a aria-describedby=\"pgen.1005895.ref025\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref025\"> 25 </a> ] and as a prognostic mutation signature in colorectal cancer [ <a aria-describedby=\"pgen.1005895.ref026\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref026\"> 26 </a> ]. Our study indicated that <em> CDH10 </em> is not only the most commonly and significantly mutated gene in SCLC but also associated with poor survival in SCLC. CDH1/E-cadherin, the founding member of the CDH/cadherin family, undergoes loss-of-function mutations across multiple tumor types such as breast, gastric, colorectal and ovarian cancer. Its functional inactivation contributes to cancer progression by increasing cell invasion, migration, metastasis and proliferation and EMT process [ <a aria-describedby=\"pgen.1005895.ref027\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref027\"> 27 </a> ]. We speculate that the recurrent CDH10 mutations we detected in SCLC may perform similar roles as CDH1 mutations in other cancers to promote SCLC aggressiveness, leading to poor patient survival. We are currently conducting experiments to test this hypothesis. </p> <p> Our study suggests that genetic alteration of DNA repair pathways influence chemotherapy outcomes in SCLC patients. The Fanconi anemia (FA) pathway is essential for the repair of DNA inter-strand cross-linking agents, such as cisplatin, which has been used as first-line treatment in SCLC. It was demonstrated several decades ago that the FA patient-derived cells which contain genetic defects in FA genes display hypersensitivity to DNA cross-linking agents [ <a aria-describedby=\"pgen.1005895.ref028\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref028\"> 28 </a> ]. Our data strongly suggest that high prevalence mutations in FA pathway genes may contribute to initial hypersensitivity of SCLC to platinum-based treatment such as cisplatin. Multiple reports with experimental evidence show that the efficacy of various chemotherapeutic agents, including cisplatin, requires a functional TP53 protein for efficient induction of apoptosis and that loss of TP53 function enhances resistance to cytotoxic agents used in cancer therapy [ <a aria-describedby=\"pgen.1005895.ref029\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref029\"> 29 </a> , <a aria-describedby=\"pgen.1005895.ref030\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref030\"> 30 </a> , <a aria-describedby=\"pgen.1005895.ref031\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref031\"> 31 </a> ]. Further, a combination of TP53 inactivation and MMR deficiency has also been observed to confer cisplatin resistance [ <a aria-describedby=\"pgen.1005895.ref032\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref032\"> 32 </a> ]. Our data suggest that high frequency mutations in <em> TP53 </em> combined with other DNA repair mutations such as mismatch repair, nucleotide excision repair, homologous recombination, and key DNA polymerases may confer early sensitivity and latent resistance to cisplatin in SCLC. </p> <p> Of particular importance is our discovery of the prevalence of <em> SRSF1 </em> CN gain and mRNA over-expression, and its role as a prognostic marker for poor patient survival\u2014reported for the first time in SCLC. <em> SRSF1 </em> occurs in the same protein complex with topoisomerase 1 ( <em> Top1 </em> ) [ <a aria-describedby=\"pgen.1005895.ref033\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref033\"> 33 </a> ]. Topotecan is a <em> Top1 </em> inhibitor and the only agent with regulatory approval for the treatment of relapsed SCLC [ <a aria-describedby=\"pgen.1005895.ref034\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref034\"> 34 </a> ]. In normal cells, Top1 cooperates with SRSF1 to prevent the formation of DNA-RNA hybrids (R-loops), unscheduled replication fork arrest, and genomic instability. In <em> Top1 </em> deficient cells, R-loops are formed and lead to replication fork stalling, phosphorylation of H2AX, and genomic instability. Treatment of <em> Top1+ </em> cells with diospyrin, to inhibit <em> Top1 </em> phosphorylation of SRSF1 or with a siRNA targeting SRSF1 mimics a Top1-deficient phenotype [ <a aria-describedby=\"pgen.1005895.ref035\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref035\"> 35 </a> ]. Although significant correlation between <em> SRSF1 </em> and <em> Top1 </em> gene expression is not observed in our data, our experiment clearly demonstrates that SRSF1 loss induces phosphorylated H2AX signal in SCLC cell lines, which suggests that SRSF1 may help maintain the genomic integrity of SCLC to safeguard against DNA-damage and cell death. With these factors in mind, we propose that SRSF1 may also rely on modulating H2AX signal to sustain the tumorigenicity in some SCLC tumor patients. </p> <p> In the absence of specific limited stage (LS) or extensive stage (ES) disease determination in this study and a recent comprehensive SCLC study [ <a aria-describedby=\"pgen.1005895.ref009\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref009\"> 9 </a> ], a simplified approach was used to classify SCLC patients into early and late stage disease activity. Based on known TNM information, early stage (TNM stage I/II) patients are M0, who are usually designated as LS patients, while late stage (TNM stage III/IV) patients are M1a or M1b, and usually classified into ES patients. We then evaluated <em> SRSF1 </em> expression between early (TNM stage I/II) and late stage (TNM stage III/IV) SCLC patients. Results indicated that <em> SRSF1 </em> gene expression does not significantly differ between these patient groups in both this study and the George et al study (p = 0.81 and p = 0.91, respectively; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s008\"> S8 Fig </a> </strong> ). This may suggest that SRSF1 is not the key driver of cancer metastasis in SCLC. </p> <p> SRSF1 is one of the critical downstream transcriptional targets of Myc [ <a aria-describedby=\"pgen.1005895.ref036\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref036\"> 36 </a> ]. Myc family genes ( <em> MYC </em> and <em> MYCN </em> ) were shown to have significant CN gain or amplification events in our Chinese SCLC patients (14%). SRSF1 gene over-expression in both Myc and N-Myc amplified SCLC cell lines and Myc amplified SCLC tumor patients, however, was not observed (p = 0.29 and p = 0.33, respectively), though the number of amplified cell lines or patient tumors with available gene expression data was sparse for each comparison ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s009\"> S9 Fig </a> </strong> ). </p> <p> <em> SRSF1 </em> is a key cancer driver, as demonstrated by the profound tumor-suppressive effect of specific <em> SRSF1 </em> knockdown in <em> SRSF1 </em> -amplified or overexpressed SCLC models. Previous reports demonstrate that overexpression of <em> SRSF1 </em> results in oncogenic transformation of immortalized rodent fibroblasts [ <a aria-describedby=\"pgen.1005895.ref037\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref037\"> 37 </a> ], human mammary epithelial cells [ <a aria-describedby=\"pgen.1005895.ref038\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref038\"> 38 </a> ] and mouse hepatocytes [ <a aria-describedby=\"pgen.1005895.ref039\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref039\"> 39 </a> ]. In these models, SRSF1 overexpression promoted cell proliferation, resistance to apoptosis, and formed tumors in orthotopic mouse models. It is likely that this transformation is a cumulative result of SRSF1\u2019s many different functions, including a combination of several alternatively spliced oncogenic variants in response to an increase in SRSF1 levels. A number of such variants have been identified, but these probably represent only a small fraction of potential effectors [ <a aria-describedby=\"pgen.1005895.ref040\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref040\"> 40 </a> ]. Das et al, previously summarized various spliced products of SRSF1 and isoform mechanisms driving oncogenic phenotypes [ <a aria-describedby=\"pgen.1005895.ref040\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref040\"> 40 </a> ], though these were not detected with reliability using RNASeq here\u2013a challenge with this technology that currently persists in splice variant detection, especially in FFEE specimens. Furthermore, we demonstrate here that SRSF1 mediates the activation of both PI3K/AKT and MEK/ERK pathways as evidenced by both gene expression pathway analyses and the suppression of these pathways through SRSF1 knockdown. It is interesting to note that several SRSF1-regulated targets involved in regulating cell proliferation are downstream of these two pathways, including RPS6KB1, MKNK2, and CCND1 genes [ <a aria-describedby=\"pgen.1005895.ref037\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref037\"> 37 </a> , <a aria-describedby=\"pgen.1005895.ref041\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref041\"> 41 </a> ]. <em> RPS6KB1 </em> encodes the protein S6 kinase 1, a downstream effector in the PI3K/AKT/mTOR signaling pathway and has been shown to be involved in mediating SRSF1-induced transformation [ <a aria-describedby=\"pgen.1005895.ref037\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref037\"> 37 </a> , <a aria-describedby=\"pgen.1005895.ref042\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref042\"> 42 </a> ]. <em> MKNK2 </em> is an effector in the MAPK/ERK pathway [ <a aria-describedby=\"pgen.1005895.ref043\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref043\"> 43 </a> ]. Splicing functionality has been shown to be critical for some, but not all oncogenic activities of SRSF1. An SRSF1 variant that is confined to the nucleus has been shown to be critical for its oncogenic role in mammary epithelial cells [ <a aria-describedby=\"pgen.1005895.ref038\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref038\"> 38 </a> ]. However, this variant was not able to promote tumor formation in hepatocellular xenografts [ <a aria-describedby=\"pgen.1005895.ref039\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref039\"> 39 </a> ]. In this particular model, SRSF1-mediated oncogenesis was attributed to activation of Raf-MEK-ERK pathway [ <a aria-describedby=\"pgen.1005895.ref039\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref039\"> 39 </a> ]. This demonstrates that SRSF1 can be oncogenic via both nuclear and cytosolic activities through either canonical (splicing-related) or non-canonical (AKT/ERK-related) pathways under various cellular contexts. It may be of future interest to explore and pinpoint which effector pathway of SRSF1 drives its oncogenic roles in SCLCs. In conclusion, our discovery firmly establishes SRSF1 as a compelling therapeutic target for SCLC, especially for the population with poor outcome, as predicted by <em> SRSF1 </em> over expression. </p> </section> <section id=\"sec010\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec010-anchor\"> </a> Methods </h2> <section id=\"sec011\"> <h3 class=\"pmc_sec_title\"> SCLC patient and sample summary </h3> <p> The study protocol and informed consent from all studies in this study were approved by the Ethics Committee of Shanghai Chest Hospital and Nanjing Medical University. Informed consent in writing was obtained from each patient and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of Shanghai Chest Hospital and Nanjing Medical University. </p> <p> Ninety-nine Chinese patients who were diagnosed with primary SCLC were recruited prospectively into an ongoing study at the Jiangsu Cancer Hospital or Shanghai Chest Hospital from July 2004 to July 2013. The diagnosis of SCLC was made by pathologists in the above hospitals by hematoxylin and eosin (H&amp;E) staining according to histology plus the immunohistochemistry for chromogranin A and synaptophysin. Patients were followed up prospectively via routine hospital visits or telephone calls. The phone calls were conducted by trained medical staff to patients or their family contacts once every three month until death or last time of follow-up. All patients were treated with at least one cycle of chemotherapy after surgery. The clinical features of the patients are summarized in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.t001\"> Table 1 </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s012\"> S1 Table </a> </strong> . Of the 99 patients, 25 had matched normal adjacent tissue or blood, while 74 patients only had tumor specimens. All tissues samples were FFPE archived samples collected from surgery (not biopsy). Eighty-six tumor samples were treatment na\u00efve and 13 of 99 patients were treated with standard chemotherapy before surgery. Tumor contents in each tumor and normal adjacent tissue (NAT) was assessed by H&amp;E stain and the tumor and NAT were subjected to macro-dissection and tumor purity was &gt;70%; the tumor content in each NAT was&lt; 3%. </p> <p> The Caucasian SCLC patient cohort consisted of 25 FFPE lung tumor tissue specimens with matched normal adjacent tissue pairs, which were purchased from Conversant Biologics, Inc (Huntsville, AL) ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s022\"> S11 Table </a> ) </strong> . The diagnosis of SCLC was confirmed by two independent pathologists in Medimmune by H&amp;E staining. All samples were treatment na\u00efve surgical samples. All patients were Caucasian with 24 males and 1 female. The average age of the patients was 63.3 years (range of 40\u201376 years). The tumor stages ranged from stage I to IV. The tumor and NAT were macro-dissected and tumor purity was &gt;70%; the tumor content in each NAT was&lt; 3%. </p> </section> <section id=\"sec012\"> <h3 class=\"pmc_sec_title\"> DNA sequence read mapping and variant calling </h3> <p> DNA whole exome sequence (WES) and RNA sequencing data (RNASeq) data was generated using the Illumina standard library preparation and sequencing protocols as described in [ <a aria-describedby=\"pgen.1005895.ref044\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref044\"> 44 </a> ] The SureSelect Human All Exon V5 capture kit was used to capture coding regions of genes included in the major genomic databases. Paired end FASTQ files of 90mer sequence reads for both sequence data types were provided to MedImmune. RNASeq data has been deposited into GEO under accession <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60052\" rel=\"noopener noreferrer\" target=\"_blank\"> GSE60052 </a> while WES data was deposited into dBGaP under accession 12059. </p> <p> All sequence data was QCd for read counts, quality values, kmer usage, GC-content, and all other relevant parameters with FastQC (v0.10.1). The DNA read sequences were aligned to the human genome (UCSC hg19; Feb 2009 release; Genome Reference Consortium GRCh37) using GATK (v2.3.4; [ <a aria-describedby=\"pgen.1005895.ref045\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref045\"> 45 </a> ]) and both insertion/deletion (indel) realignment and PCR duplicate removal was conducted using GATK (v2.3.4; [ <a aria-describedby=\"pgen.1005895.ref045\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref045\"> 45 </a> ]) and Picard (v1.85; [ <a aria-describedby=\"pgen.1005895.ref046\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref046\"> 46 </a> ]) respectively. Both coverage and depth statistics for all 99 tumor specimens are provided in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s021\"> S10 Table </a> . </strong> </p> <p> For the 25 tumor/normal matched Chinese and 25 tumor/normal matched Caucasian (commercially purchased) specimens, both Mutect (v1.1.4; [ <a aria-describedby=\"pgen.1005895.ref047\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref047\"> 47 </a> ]) and SAMtools (v0.1.18; [ <a aria-describedby=\"pgen.1005895.ref048\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref048\"> 48 </a> ]) were used to make somatic variant calls. SAMtools mpileup arguments: Qphred&gt;30 and mapping quality&gt;30 with minimum coverage &gt;20; MuTect arguments: default settings. GATK SomaticIndelDetector with default settings and SAMtools mpileup were used to identify small indels. The SNVs and indels which were in common between GATK and Samtools were retained. SNVs and indels were further filtered by 1000 genomes and NHLBI-ESP project with 6500 exomes minor allele frequency (MAF) in all races of &lt;1% or unknown MAF. The retained SNVs/indels were further filtered by dbSNP129 and dbSNP135, following known issues between the two dbSNP versions. Finally, genes were removed from the SNV/indel list that had been identified from a previous study as potential artifact genes, to further minimize false positive variant calls [ <a aria-describedby=\"pgen.1005895.ref049\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref049\"> 49 </a> ] All dbSNPs which were retained in dbSNP135 and had Cosmic IDs were noted for further study. </p> <p> For the 74 DNA tumor specimens without a matched normal specimen, Samtools mpileup was used to call SNVs and indels relative to the human reference genome (UCSC hg19; Feb 2009 release; Genome Reference Consortium GRCh37). Germline polymorphisms were removed by retaining only mutations with MAF in all races of &lt;1% or unknown MAF within the 1000 genomes and NHLBI-ESP project with 6500 exomes database. The retained SNVs/indels were further filtered by dbSNP129 and dbSNP135 similar to previously described. The most recurrent SNVs/indels between the matched and unmatched patient cohorts are provided in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s013\"> S2 Table </a> </strong> , along with patient recurrence summaries from a previous Japanese SCLC cohort of 51 patients, to highlight comparability in results and a validation of the SNV/indel calling strategy [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. A similar strategy for calling and filtering somatic SNVs in the absence of a matched germline control specimen was conducted in a previous prostate cancer whole exome study [ <a aria-describedby=\"pgen.1005895.ref050\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref050\"> 50 </a> ]. All patient-level somatic SNV or indel calls with associated read depth and annotation parameters are provided in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s019\"> S8 Table </a> </strong> . </p> <p> SNV and indel annotation was conducted with ANNOVAR [ <a aria-describedby=\"pgen.1005895.ref051\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref051\"> 51 </a> ] </p> </section> <section id=\"sec013\"> <h3 class=\"pmc_sec_title\"> Patient identity QC </h3> <p> To verify the identity and matching between the tumor and normal paired WES samples, a selection of 300 heterozygous single nucleotide polymorphisms (SNPs) with MAFs&gt;0.3 and &lt;0.7 were selected from the 1000 genomes database. All DNA samples were clustered to observe any major discrepancies in subject or specimen labeling ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s010\"> S10 Fig </a> </strong> ). </p> </section> <section id=\"sec014\"> <h3 class=\"pmc_sec_title\"> Recurrent driver gene identification </h3> <p> All somatic mutations in the coding regions (plus splicing mutations) were selected for driver gene prediction analysis to identify those genes with the most recurrent nonsilent mutations. MutsigCV [ <a aria-describedby=\"pgen.1005895.ref039\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref039\"> 39 </a> ] and the method described by Youn et al [ <a aria-describedby=\"pgen.1005895.ref052\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref052\"> 52 </a> ] were implemented independently and Q value&lt;0.05(MutsigCV) and Q value = 0.00 (Youn\u2019s method) were used as thresholds to detect significantly recurrently mutated genes. Genes predicted by both methods were selected as high confidence driver genes ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s014\"> S3 Table </a> ) </strong> . </p> </section> <section id=\"sec015\"> <h3 class=\"pmc_sec_title\"> DNA polymerases structure modeling </h3> <p> Amino acid change mutations were mapped onto corresponding structures using mutagenesis wizard implemented in PyMOL (Schrodinger, LLC). For POLG coordinates of human mitochondrial DNA polymerase holoenzyme from Protein Data Bank (PDB, [ <a aria-describedby=\"pgen.1005895.ref053\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref053\"> 53 </a> ]) entry 3IKM [ <a aria-describedby=\"pgen.1005895.ref054\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref054\"> 54 </a> ] were used. The Q52E mutation could not be mapped since that part of the protein was absent in the structure. For DNA polymerase delta subunit the PDB entry 3IAY of yeast that shares 48/65% sequence identity/similarity over 908 amino acids was used. </p> </section> <section id=\"sec016\"> <h3 class=\"pmc_sec_title\"> RNA sequence read mapping and differential expression analysis </h3> <p> For RNASeq data, the average read count per mate was 50 million. RNA reads were mapped to the human genome (UCSC hg19; Feb 2009 release; Genome Reference Consortium GRCh37) using TopHat2 (v2.0.9; [ <a aria-describedby=\"pgen.1005895.ref055\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref055\"> 55 </a> , <a aria-describedby=\"pgen.1005895.ref056\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref056\"> 56 </a> ]) and the human reference gtf annotation file (GRCh37.68). Transcript counts were calculated and normalized using htseq-count and DESeq (v1.12.1; [ <a aria-describedby=\"pgen.1005895.ref057\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref057\"> 57 </a> ]). The DESeq negative binomial distribution was used to calculate the p-value and fold changes between 48 lung tumor and 6 normal adjacent lung samples using adjusted p&lt;0.05 and |fold change|&gt;2 as a threshold. The full transcriptome summary table is provided ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s020\"> S9 Table </a> </strong> ). Due to the low fidelity and lack of reproducibility in splice variant detection using RNASeq, analysis was not conducted to examine spliced products of SRSF1. </p> </section> <section id=\"sec017\"> <h3 class=\"pmc_sec_title\"> Somatic copy number variation (CNV) analysis </h3> <p> For CNV analysis, the R package ExomeCNV [ <a aria-describedby=\"pgen.1005895.ref058\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref058\"> 58 </a> ] was used. This method makes CNV calls not by defining a mandatory cut-off to detect gains or losses, rather the specificity and sensitivity (power) of detecting CNV based on depth of coverage and log ratio of all exons is calculated, and a CN call is made when sufficient specificity and sensitivity are achieved. We used default parameters setting of ExomeCNV (sensitivity and specificity = 99.9%). For the 22 tumor/normal matched Chinese as well as the 25 tumor/normal Caucasian (commercially purchased) specimens, the standard ExomeCNV pipeline was employed, in which a tumor and its adjacent normal pair were used to make the call. For the 74 tumor specimens without matched normal tissue, 1 normal FFPE lung tissue specimen (N08-4579A) was used as baseline with each of the 74 tumor specimens using ExomeCNV. This method was also conducted with 6 normal FFPE lung tissue specimens and results were very similar between the use of a single normal or average of 6 normals. The overview of the most prevalent CNV calls (\u226520% patients harboring gains or losses, to limit the table size) for matched Chinese patient tumor/normal or Chinese patient tumor only results are provided in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s016\"> S5 Table </a> </strong> . </p> </section> <section id=\"sec018\"> <h3 class=\"pmc_sec_title\"> TCGA data to evaluate SRSF1 CN gain correlation with survival in other indications </h3> <p> All cancer indications in TCGA were assessed for correlation with survival using OncoLand (OmicSoft Corp; Cary, NC). To avoid issues of unbalanced comparisons, only indications where at least 3 patients harboring a CN gain in SRSF1 were analyzed. These included: breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), sarcoma (SARC), skin cutaneous melanoma (SKCM), and uterine corpus endometrioid carcinoma (UCEC). UCEC was the only indication with a correlation between patients harboring CN gain of SRSF1 and poor survival (log-rank test p = 0.003), though the number of patients harboring a CN gain was highly unbalanced compared to those without (n = 8 vs. n = 437, respectively; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s003\"> S3 Fig </a> </strong> ). </p> </section> <section id=\"sec019\"> <h3 class=\"pmc_sec_title\"> Time-to-event analyses </h3> <p> Time-to-event analyses were used to correlate both the CN gain status of <em> SRSF1 </em> and <em> SRSF1 </em> gene expression with overall survival of Chinese SCLC patients. First, a Kaplan-Meier (KM) analysis was used to evaluate the difference of survival curves for <em> SRSF1 </em> CN gain group and no CN gain group. Those genes with a trend of significance (log-rank p&lt;0.1) in the Chinese patient discovery cohort (n = 22; <em> SRSF1 </em> in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3D </a> </strong> ) and with 10% CNV calls among the cohort were evaluated in the Chinese patient validation cohort (n = 74; 1,707 genes; <em> SRSF1 </em> in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3E </a> </strong> ). Since the discovery cohort was approximately 1/3 the size of the validation cohort and thus less powered, a modest log-rank test threshold was used. Among those 1,707 genes, 215 had p-values&lt;0.05 from the log-rank test and CNV calls in more than 10% of the patients in the cohort. Among these 215 genes, <em> SRSF1 </em> was the only gene that correlated with DNA CN gain status using a Welch\u2019s modified t-test (p&lt;0.01; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3B </a> </strong> ). </p> <p> Next, both the Chinese patient discovery and validation cohorts were combined (n = 96) and both a KM and multivariate Cox proportion hazard (PH) regression analysis was conducted to compare the <em> SRSF1 </em> CN gain and no CN gain patient groups. Differences were assessed with p-values for the grouping difference (log-rank) and the hazard ratio with adjustment for age, gender, tumor stage and chemotherapy treatment status before sampling (Cox PH model; <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3F </a> </strong> ). </p> <p> Then, the gene expression of <em> SRSF1 </em> in the 48 Chinese SCLC patients with RNASeq and clinical data were divided into two groups according to <em> SRSF1 </em> gene expression level (&gt;75% percentile of overall expression and &lt; = 75% percentile of overall expression). Similar KM analysis as well as a Cox PH regression analysis was performed to compare the survival curves of <em> SRSF1 </em> over- expressed versus not over-expressed groups with the same covariate adjustments in the Cox PH model as conducted previously with WES data ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3C </a> </strong> ). The R package survival was used to perform these analyses and model summaries are provided in both <strong> <a class=\"usa-link\" href=\"#pgen.1005895.g003\"> Fig 3 </a> </strong> and <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s018\"> S7A and S7B Table </a> </strong> . </p> <p> A similar time-to-event analysis adjusting for age, gender, tumor stage and chemotherapy treatment status was conducted using the nonsilent mutation status to split patients into two groups. </p> </section> <section id=\"sec020\"> <h3 class=\"pmc_sec_title\"> FISH confirmation of SRSF1 CN gain status </h3> <p> SRSF1 gene copy number change was conducted via a dual-probe FISH test. The SRSF1 FISH probe was a SpectrumRed (Cat #02N34-050, Enzo Life Sciences, Inc., New York, USA) labeled fluorescent DNA probe, generated in-house from a bacterial artificial clone CTD-2061E5 (Invitrogen, Carlsbad, USA). CEP17 probe (Vysis, Cat #06J37-017) was a SpectrumGreen labeled fluorescent DNA probe specific for the alpha satellite DNA sequence at the centromeric region of chromosome 17. </p> <p> FISH assays were performed as reported previously. In brief, assays were run on 4 micron dewaxed and dehydrated FFPE samples from 34 small cell lung cancer patients. The SpotLight Tissue pretreatment Kit (Cat #00\u20138401, Invitrogen, Carlsbad, USA) was used for pretreatment according to the manufacturer\u2019s instructions. Sections and probes were codenaturated at 79oC for 6 minutes and then hybridized at 37oC for 48 hours. After a quick post wash off process (0.3%NP40/2xSSC at 75.5 oC for 2 minutes, twice in 2\u00d7SSC at room temperature for 2 minutes), sections were finally mounted with 0.3\u03bcg/ml DAPI (Cat #H-1200, Vector Laboratories, Inc., Burlingame, USA). </p> <p> CN gains were scored using the criteria outlined by Cappuzzo et al (18) where disomy was scored by \u22642 copies in \u226590% of cells, low trisomy was scored by \u22642 copies in \u226540% of cells and \u22653 copies in 10\u201340% of the cells, high trisomy was scored by \u22642 copies in \u226540% of the cells and \u22653 copies in \u226540% of the cells, and polysomy was scored by \u22642 copies in &lt;40% of the cells. High trisomy and polysomy were called CN gain positive. ( <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s017\"> S6 Table </a> </strong> ). </p> </section> <section id=\"sec021\"> <h3 class=\"pmc_sec_title\"> Taqman assay for SRSF1 CNV status in SCLC cell lines </h3> <p> Genomic DNA (gDNA) from cultured cells was prepared using QIAamp DNA Micro Kit. Copy number assay of SRSF1 (Hs00944074_cn) and reference assay RNase P (VIC) were ordered from ABI/Life Technologies. Assays were set up based on ABI reference with four replicates for each sample. The assays were run on ABI 7900HT (SDS v2.X) and the data files were analyzed using the CopyCaller Software. Reference probe RNAse-P was used to determine the SRSF1 copy number gain status: copy number &gt; 2 was considered a gain status. </p> </section> <section id=\"sec022\"> <h3 class=\"pmc_sec_title\"> Cell culture, antibodies, and function assays </h3> <p> All SCLC cell lines were grown in RPMI1640 medium supplemented with 10% fetal bovine serum. SRSF1 (SF2/ASF) antibody (96) was supplied by Santa Cruz Biotechnology. Phospho-Histone H2A.X (Ser139) (20E3) and Phospho-Chk2 (Thr68) (C13C1) were supplied by Cell Signaling Technology. Cell proliferation was determined by CellTiter-Glo Luminescent Cell Viability Assay (Promega). Caspase-Glo 3/7 Assay Systems (Promega) were used to analyze cell apoptosis. </p> </section> <section id=\"sec023\"> <h3 class=\"pmc_sec_title\"> siRNA transfection </h3> <p> SiRNA reverse transfections were carried out using Lipofectamine RNAiMAX (Life Technologies). siRNAs targeting SRSF1 were ordered as \u201cHP custom siRNA\u201d from Qiagen. The sequences is and CCAACAAGATAGAGTATAA (SRSF1 siRNA). AllStars Neg. Control siRNA (Qiagen) was used as negative control for transfection. Both control siRNA and SRSF1 siRNAs were transfected at a final concentration of 100nM. Culture medium were was replaced with fresh medium at 48 hour after transfection, and cell lysates were prepared at 72 hour for Western blotting. </p> </section> <section id=\"sec024\"> <h3 class=\"pmc_sec_title\"> Colony formation assays </h3> <p> For clonogenic assay, SCLC cell lines were transfected with SRSF1 siRNAs for 48 hrs and then seeded in a 1% methylcellulose H4100 medium (StemCell Technologies) consisting of RPMI1640 medium with 10% FBS at 2,000 cells/mL. After 5 days, colonies with more than 40 cells per colony were counted. </p> </section> <section id=\"sec025\"> <h3 class=\"pmc_sec_title\"> Sphere forming assays </h3> <p> SCLC cell lines were transfected with SRSF1 siRNAs for 48 hrs and then seeded in ultralow attachment plates (Corning) in sphere forming media: DMEM/F12 with 0.4% BSA, 10ng/mL bFGF, 20ng/mL EGF, 5ug/mL insulin, 1% KnockOut Serum Replacement (Life Technologies). Cells were treated with Cisplatin (0.001 ug\u2013 10 ug/ml) for 4 days, after which viability of spheres was quantitated by CellTiter-Glo Assay (Promega). Images were taken with EVOS FL Auto Cell Imaging System. </p> </section> <section id=\"sec026\"> <h3 class=\"pmc_sec_title\"> SRSF1 rescue assays </h3> <p> SCLC cell lines were cotransfected with 800 ng myc/flag-tagged SRSF1 vector (Origene) encoding the open reading frame of either the wildtype gene ( <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nuccore/NM_006924.4\" rel=\"noopener noreferrer\" target=\"_blank\"> NM_006924.4 </a> with 25 nM of either non-targeting siRNA or SRSF1 siRNA-2 using Lipofectamine RNAiMAX (Life Technologies). SRSF1 siRNA targets the 3\u2019UTR of SRSF1, and therefore does not affect expression of the SRSF1 ORF vector. After 48 hr, cells were harvested and then seeded in ultralow attachment plates (Corning) in sphere forming media: DMEM/F12 with 0.4% BSA, 10ng/mL bFGF, 20ng/mL EGF, 5ug/mL insulin, 1% KnockOut Serum Replacement (Life Technologies). Cells were also harvested and lysed with Novex Tris-Glycine SDS Sample Buffer (Life Technologies) for Western blotting. Viability of spheres was quantitated after 4 days by CellTiter-Glo Assay (Promega). Images were taken with EVOS FL Auto Cell Imaging System </p> </section> <section id=\"sec027\"> <h3 class=\"pmc_sec_title\"> Xenograft studies in mice </h3> <p> All animal procedures were conducted in accordance with all appropriate regulatory standards under protocols approved by the Medimmune Institutional Animal Care and Use Committee. Since the SRSF1 siRNA had shown good knockdown efficacy of SRSF1 protein at day7 after transient transfection (by western blot of sphere assays), and prolonged effects on colony formation (about 2 weeks after transfection), we used transient siRNA knockdown in the mice xenograft study. Immunocompromised athymic nude (nu/nu) female mice were purchased from Harlon Laboratories at 3\u20134 week of age. SHP-77 and DMS-114 cells were transfected with either control siRNA or SRSF1 siRNA at a final concentration of 100nM. Two days after transfection, ten million viable cells in 50% matrigel were inoculated subcutaneously (SC) into right flank of each mouse. The length and width of each tumor was measured with an electronic cliper 2 times per week. Tumor growth curves of DMS114 and SHP77 parental cell lines are displayed in <strong> <a class=\"usa-link\" href=\"#pgen.1005895.s011\"> S11 Fig </a> </strong> . Tumor volume (mm3) was calculated based on the following formula: [length (mm) x width (mm)2] \u00f7 2. </p> </section> </section> <section id=\"sec028\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec028-anchor\"> </a> Supporting Information </h2> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s001\"> <div class=\"caption p\"> <span> S1 Fig. Genomic alterations in Chinese SCLC patients. </span> <p> Tumor samples (n = 99) are ordered from left to right based on SRSF1 copy number gains. Mutations and DNA copy number alterations of key SCLC oncogenic genes are indicated for each sample according to the color legend below the figure. The genomic alteration frequencies for each candidate gene are displayed on the left. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s001.docx\"> Click here for additional data file. </a> <sup> (72.4KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s002\"> <div class=\"caption p\"> <span> S2 Fig. SRSF1 gene copy number detection by FISH. </span> <p> Representative images show a) SRSF1 normal and b) SRSF1 copy number gain. Red signals represent SRSF1 gene and green signals represent of CEP17; c) SRSF1 CNV SCLC patient prevalence as well as other CNV segments across chromosome 17. Red lines indicate CN gains and green lines indicate CN losses. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s002.docx\"> Click here for additional data file. </a> <sup> (3.1MB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s003\"> <div class=\"caption p\"> <span> S3 Fig. KM curves from indications in TCGA where at least 3 patients harbored a CN gain of SRSF1. </span> <p> Plots were generated in OncoLand (OmicSoft Corp; Cary, NC). </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s003.docx\"> Click here for additional data file. </a> <sup> (111.5KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s004\"> <div class=\"caption p\"> <span> S4 Fig </span> <p> (a): TaqMan assays of SRSF1 DNA CNs in 13 SCLC cell lines. (b): Western blots of SRSF1 show protein expression levels in SCLC cell lines. (c):NCI-H82, SHP-77 and NCI-H1048 were transfected with non-targeting control or SRSF1-directed siRNAs for 48 hrs, then treated with cisplatin (2.5ug/ml) or topotecan (2.5ug/ml) for 24 hrs. Cell growth and Caspase-3/7 activities were assessed and normalized against ctrl siRNA-transfected cells as 100% control. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s004.docx\"> Click here for additional data file. </a> <sup> (214.4KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s005\"> <div class=\"caption p\"> <span> S5 Fig. The association of SRSF1 gene expression with BIM gene expression in Chinese SCLC patients (N = 49). </span> <p> The correlation between SRSF1 and BIM gene expression is significant, which likely confirms SRSF1 over expression promotes alternative splicing of BIM. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s005.docx\"> Click here for additional data file. </a> <sup> (100.2KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s006\"> <div class=\"caption p\"> <span> S6 Fig. NCI-82, SHP-77 and NIH-H1048 cells were transfected with non-targeting and SRSF1 siRNAs respectively for 48 hrs and then seeded in sphere forming media and allowed to grow for 4 days. </span> <p> (a): Phase-contrast images of the sphere formation under each condition were captured. (b): viable cell mass quantitated by CTG assay. (c): Reconstitution of SRSF1 expression using a siRNA-resistant Flag-tagged SRSF1 expression construct was carried out in SRSF1 siRNA transfected NCI-H82 cells. Impact on sphere growth rate was assessed by CTG assay, and successful SRSF1 protein re-expression was confirmed by WB using either anti-SRSF1 antibody or anti-Flag antibody. (d): Clonogenic assays of DMS-114, NCI-82, SHP-77 and NIH-H1049. Cells were transfected with siRNAs for 48 hrs and then seeded in the methylcellulose medium for 7~14 days, colonies with more than 40 cells per colony were counted. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s006.docx\"> Click here for additional data file. </a> <sup> (193.2KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s007\"> <div class=\"caption p\"> <span> S7 Fig </span> <p> (a)SHP-77 cells transfected with non-targeting control siRNA or SRSF1 siRNA were implanted into immunocompromised mice and tumor formation rates were monitored and measured. (b): SHP-77 cells were transfected with control or SRSF1 siRNA and then treated with topotecan or Cisplatin for the indicated times. SRSF1, phosphor-H2AX and phosphor-Chk2 were probed with their corresponding antibodies. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s007.docx\"> Click here for additional data file. </a> <sup> (135.6KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s008\"> <div class=\"caption p\"> <span> S8 Fig. The association of SRSF1 gene expression with early stage and late stage (ES) SCLC patients in both our Chinese SCLC study (left figure) and George et al, study (right figure). </span> <p> P-value is calculated using Welch\u2019s modified t-test. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s008.docx\"> Click here for additional data file. </a> <sup> (125.6KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s009\"> <div class=\"caption p\"> <span> S9 Fig. The association of SRSF1 gene expression with MYC CNV status. </span> <p> SCLC cell lines (left figure, N = 11) and our Chinese SCLC study (right figure, N = 49 patients with matched expression and CNV samples). P-value is estimated using standard t-test. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s009.docx\"> Click here for additional data file. </a> <sup> (125KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s010\"> <div class=\"caption p\"> <span> S10 Fig. Identity check between matched SCLC tumor and normal specimens. </span> <p> Pearson correlation heatmap is used to compare 300 germline SNP profiles between each of the 25 tumors and matched normals. Gradient of colors: green = no correlation; yellow = low correlation; white = high correlation. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s010.docx\"> Click here for additional data file. </a> <sup> (113.5KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s011\"> <div class=\"caption p\"> <span> S11 Fig. Tumor growth curves for DMS114 and SHP77 parental cell lines. </span> <p> A total of 5\u201310 millioins cells were injected to establish xenograft tumors. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s011.docx\"> Click here for additional data file. </a> <sup> (79.9KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s012\"> <div class=\"caption p\"> <span> S1 Table. Chinese patient clinical summary (n = 99). </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s012.xlsx\"> Click here for additional data file. </a> <sup> (21.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s013\"> <div class=\"caption p\"> <span> S2 Table. Recurrent somatic mutated genes from 99 Chinese SCLC patients; additional recurrent rates from 51 SCLC Japanese patients in an independent study [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s013.xlsx\"> Click here for additional data file. </a> <sup> (93.1KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s014\"> <div class=\"caption p\"> <span> S3 Table. Cancer driver gene intersection by two methods and two public data sets in 99 Chinese SCLC. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s014.xlsx\"> Click here for additional data file. </a> <sup> (21.3KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s015\"> <div class=\"caption p\"> <span> S4 Table. SNVs within DNA repair mechanisms in Chinese SCLC patients (n = 99) using nonsilent somatic SNVs and indels. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s015.xlsx\"> Click here for additional data file. </a> <sup> (64.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s016\"> <div class=\"caption p\"> <span> S5 Table. Patient counts harboring recurrent (prevalence&gt;20%) gene-level somatic CNVs in discovery and validation cohorts (n = 96). </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s016.xlsx\"> Click here for additional data file. </a> <sup> (284.7KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s017\"> <div class=\"caption p\"> <span> S6 Table. FISH assay confirmation of WES CN calls for SRSF1. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s017.xlsx\"> Click here for additional data file. </a> <sup> (16.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s018\"> <div class=\"caption p\"> <span> S7 Table </span> <p> A. Kaplan-Meier analysis summary for SRSF1 DNA amplification and mRNA expression; B. Cox proportion hazard regression analysis summary for SRSF1 DNA amplification and mRNA over-expression. </p> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s018.xlsx\"> Click here for additional data file. </a> <sup> (17KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s019\"> <div class=\"caption p\"> <span> S8 Table. Patient-specific somatic nonsilent SNVs/indels from 99 Chinese SCLC patients. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s019.xlsx\"> Click here for additional data file. </a> <sup> (3.9MB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s020\"> <div class=\"caption p\"> <span> S9 Table. Gene expression (RNASeq) of top up/down regulated genes between 48 tumor and 6 normal samples. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s020.xlsx\"> Click here for additional data file. </a> <sup> (160.9KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s021\"> <div class=\"caption p\"> <span> S10 Table. WES coverage and depth statistics for 99 tumor specimens. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s021.xlsx\"> Click here for additional data file. </a> <sup> (21.9KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s022\"> <div class=\"caption p\"> <span> S11 Table. Commercial Caucasian patient information. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s022.xlsx\"> Click here for additional data file. </a> <sup> (12.8KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"pgen.1005895.s023\"> <div class=\"caption p\"> <span> S12 Table. Mater Regulator Analysis (Ingenuity Pathway Analysis) for differential expression genes between SRSF1 CN Gain / Amp and SRSF1 CN Neutral. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s023.xlsx\"> Click here for additional data file. </a> <sup> (16KB, xlsx) </sup> </div> </div> </section> </section> <section class=\"ack\" id=\"ack1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ack1-anchor\"> </a> Acknowledgments </h2> <p> We thank all the study participants who took part in this work. We also thank Beijing Genomics Institute and WuXi AppTec for exome and RNA sequencing presented in this study. </p> </section> <section id=\"notes1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"notes1-anchor\"> </a> Data Availability </h2> <p> All analysis results are within the paper and its Supporting Information files. RNASeq data has been deposited into GEO under accession GSE60052 ( <a class=\"usa-link\" href=\"http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60052\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60052 </a> ); while WES data was deposited into dBGaP under accession ID phs001083.v1.p1 ( <a class=\"usa-link\" href=\"http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001083.v1.p1\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001083.v1.p1 </a> .) </p> </section> <section id=\"funding-statement1\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"funding-statement1-anchor\"> </a> Funding Statement </h2> <p> This study was supported by MedImmune/AstraZeneca. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </p> </section> <section class=\"ref-list\" id=\"ref-list1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ref-list1-anchor\"> </a> References </h2> <section id=\"ref-list1_sec2\"> <ul class=\"ref-list font-sm\"> <li id=\"pgen.1005895.ref001\"> <span class=\"label\"> 1. </span> <cite> Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin. Proc. 2008;83:355\u2013367. 10.4065/83.3.355 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.4065/83.3.355\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/18316005/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mayo%20Clin.%20Proc&amp;title=Small%20cell%20lung%20cancer&amp;author=T%20Sher&amp;author=GK%20Dy&amp;author=AA%20Adjei&amp;volume=83&amp;publication_year=2008&amp;pages=355-367&amp;pmid=18316005&amp;doi=10.4065/83.3.355&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref002\"> <span class=\"label\"> 2. </span> <cite> Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21:2244\u201355. 10.1158/1078-0432.CCR-14-2958 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1078-0432.CCR-14-2958\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4497796/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25979931/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Small%20cell%20lung%20cancer:%20will%20recent%20progress%20lead%20to%20improved%20outcomes?&amp;author=MC%20Pietanza&amp;author=LA%20Byers&amp;author=JD%20Minna&amp;author=CM%20Rudin&amp;volume=21&amp;publication_year=2015&amp;pages=2244-55&amp;pmid=25979931&amp;doi=10.1158/1078-0432.CCR-14-2958&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref003\"> <span class=\"label\"> 3. </span> <cite> Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012; 44:1111\u20136. 10.1038/ng.2405 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ng.2405\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3557461/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22941189/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Comprehensive%20genomic%20analysis%20identifies%20SOX2%20as%20a%20frequently%20amplified%20gene%20in%20small-cell%20lung%20cancer&amp;author=CM%20Rudin&amp;author=S%20Durinck&amp;author=EW%20Stawiski&amp;author=JT%20Poirier&amp;author=Z%20Modrusan&amp;volume=44&amp;publication_year=2012&amp;pages=1111-6&amp;pmid=22941189&amp;doi=10.1038/ng.2405&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref004\"> <span class=\"label\"> 4. </span> <cite> Peifer M, Fern\u00e1ndez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104\u201310. 10.1038/ng.2396 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ng.2396\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4915822/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22941188/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Integrative%20genome%20analyses%20identify%20key%20somatic%20driver%20mutations%20of%20small-cell%20lung%20cancer&amp;author=M%20Peifer&amp;author=L%20Fern%C3%A1ndez-Cuesta&amp;author=ML%20Sos&amp;author=J%20George&amp;author=D%20Seidel&amp;volume=44&amp;publication_year=2012&amp;pages=1104-10&amp;pmid=22941188&amp;doi=10.1038/ng.2396&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref005\"> <span class=\"label\"> 5. </span> <cite> Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014;9:1324\u201331. 10.1097/JTO.0000000000000250 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1097/JTO.0000000000000250\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4154841/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25122428/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Therapeutic%20priority%20of%20the%20PI3K/AKT/mTOR%20pathway%20in%20small%20cell%20lung%20cancers%20as%20revealed%20by%20a%20comprehensive%20genomic%20analysis&amp;author=S%20Umemura&amp;author=S%20Mimaki&amp;author=H%20Makinoshima&amp;author=S%20Tada&amp;author=G%20Ishii&amp;volume=9&amp;publication_year=2014&amp;pages=1324-31&amp;pmid=25122428&amp;doi=10.1097/JTO.0000000000000250&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref006\"> <span class=\"label\"> 6. </span> <cite> Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269\u2013271. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1126/science.1102160\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/15472075/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Activating%20mutations%20of%20NOTCH1%20in%20human%20T%20cell%20acute%20lymphoblastic%20leukemia&amp;author=AP%20Weng&amp;author=AA%20Ferrando&amp;author=W%20Lee&amp;volume=306&amp;publication_year=2004&amp;pages=269-271&amp;pmid=15472075&amp;doi=10.1126/science.1102160&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref007\"> <span class=\"label\"> 7. </span> <cite> Park MJ, Taki T, Oda M, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1111/j.1365-2141.2009.07607.x\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19245433/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=FBXW7%20and%20NOTCH1%20mutations%20in%20childhood%20T%20cell%20acute%20lymphoblastic%20leukaemia%20and%20T%20cell%20non-Hodgkin%20lymphoma&amp;author=MJ%20Park&amp;author=T%20Taki&amp;author=M%20Oda&amp;publication_year=2009&amp;pmid=19245433&amp;doi=10.1111/j.1365-2141.2009.07607.x&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref008\"> <span class=\"label\"> 8. </span> <cite> Adolfo A. Ferrando, The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009; 353\u2013361 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1182/asheducation-2009.1.353\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2847371/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20008221/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Hematology%20Am%20Soc%20Hematol%20Educ%20Program&amp;title=The%20role%20of%20NOTCH1%20signaling%20in%20T-ALL&amp;author=A%20Adolfo&amp;author=%20Ferrando&amp;volume=353%E2%80%93361&amp;publication_year=2009&amp;pmid=20008221&amp;doi=10.1182/asheducation-2009.1.353&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref009\"> <span class=\"label\"> 9. </span> <cite> George Julie, Jing Shan Lim, Se Jin Jang, Cun Yupeng, Luka Ozreti\u0107 Gu Kong, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524, 47\u201353. 10.1038/nature14664 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature14664\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4861069/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26168399/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20genomic%20profiles%20of%20small%20cell%20lung%20cancer&amp;author=Julie%20George&amp;author=Shan%20Lim%20Jing&amp;author=Jang%20Se%20Jin&amp;author=Yupeng%20Cun&amp;author=Gu%20Kong%20Luka%20Ozreti%C4%87&amp;volume=524&amp;publication_year=2015&amp;pages=47-53&amp;pmid=26168399&amp;doi=10.1038/nature14664&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref010\"> <span class=\"label\"> 10. </span> <cite> The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature; 489, 519\u2013525 10.1038/nature11404 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature11404\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3466113/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22960745/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20genomic%20characterization%20of%20squamous%20cell%20lung%20cancers&amp;volume=489&amp;pages=519-525&amp;pmid=22960745&amp;doi=10.1038/nature11404&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref011\"> <span class=\"label\"> 11. </span> <cite> Kools P, Vanhalst K, Van den Eynde E, van Roy F. The human cadherin-10 gene: complete coding sequence, predominant expression in the brain, and mapping on chromosome 5p13-14. FEBS Lett. 1999; 452: 328\u201334. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/s0014-5793(99)00672-9\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/10386616/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett&amp;title=The%20human%20cadherin-10%20gene:%20complete%20coding%20sequence,%20predominant%20expression%20in%20the%20brain,%20and%20mapping%20on%20chromosome%205p13-14&amp;author=P%20Kools&amp;author=K%20Vanhalst&amp;author=E%20Van%20den%20Eynde&amp;author=F%20van%20Roy&amp;volume=452&amp;publication_year=1999&amp;pages=328-34&amp;pmid=10386616&amp;doi=10.1016/s0014-5793(99)00672-9&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref012\"> <span class=\"label\"> 12. </span> <cite> Wood RD, Mitchell M, Lindahl T. Human DNA repair genes. Mutat Res. 2005;577: 275\u201383. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.mrfmmm.2005.03.007\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/15922366/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mutat%20Res&amp;title=Human%20DNA%20repair%20genes&amp;author=RD%20Wood&amp;author=M%20Mitchell&amp;author=T%20Lindahl&amp;volume=577&amp;publication_year=2005&amp;pages=275-83&amp;pmid=15922366&amp;doi=10.1016/j.mrfmmm.2005.03.007&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref013\"> <span class=\"label\"> 13. </span> <cite> Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nature Reviews Cancer. 2011;2: 96\u2013110. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nrc2998\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3739438/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21258395/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Cancer&amp;title=DNA%20polymerases%20and%20cancer&amp;author=SS%20Lange&amp;author=K%20Takata&amp;author=RD%20Wood&amp;volume=2&amp;publication_year=2011&amp;pages=96-110&amp;pmid=21258395&amp;doi=10.1038/nrc2998&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref014\"> <span class=\"label\"> 14. </span> <cite> Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6: 789\u2013802. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nrc1977\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/16990856/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Topoisomerase%20I%20inhibitors:%20camptothecins%20and%20beyond&amp;author=Y%20Pommier&amp;volume=6&amp;publication_year=2006&amp;pages=789-802&amp;pmid=16990856&amp;doi=10.1038/nrc1977&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref015\"> <span class=\"label\"> 15. </span> <cite> Arriola E, Ca\u00f1adas I, Arum\u00ed M, Rojo F, Rovira A, Albanell J. Genetic changes in small cell lung carcinoma. Clin Transl. Oncol. 2008;10: 189\u2013197. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1007/s12094-008-0181-1\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/18411191/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Transl.%20Oncol&amp;title=Genetic%20changes%20in%20small%20cell%20lung%20carcinoma&amp;author=E%20Arriola&amp;author=I%20Ca%C3%B1adas&amp;author=M%20Arum%C3%AD&amp;author=F%20Rojo&amp;author=A%20Rovira&amp;volume=10&amp;publication_year=2008&amp;pages=189-197&amp;pmid=18411191&amp;doi=10.1007/s12094-008-0181-1&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref016\"> <span class=\"label\"> 16. </span> <cite> D\u2019Angelo SP. Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther. 2010;10: 1\u201310. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.4161/cbt.10.1.12045\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21361067/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Biol%20Ther&amp;title=Pietanza%20MC.%20The%20molecular%20pathogenesis%20of%20small%20cell%20lung%20cancer&amp;author=SP%20D%E2%80%99Angelo&amp;volume=10&amp;publication_year=2010&amp;pages=1-10&amp;pmid=21361067&amp;doi=10.4161/cbt.10.1.12045&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref017\"> <span class=\"label\"> 17. </span> <cite> Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum. Mol. Genet. 2009;18:1343\u20131352. 10.1093/hmg/ddp034 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/hmg/ddp034\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19153074/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Hum.%20Mol.%20Genet&amp;title=The%20SRY-HMG%20box%20gene,%20SOX4,%20is%20a%20target%20of%20gene%20amplification%20at%20chromosome%206p%20in%20lung%20cancer&amp;author=PP%20Medina&amp;author=SD%20Castillo&amp;author=S%20Blanco&amp;author=M%20Sanz-Garcia&amp;author=C%20Largo&amp;volume=18&amp;publication_year=2009&amp;pages=1343-1352&amp;pmid=19153074&amp;doi=10.1093/hmg/ddp034&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref018\"> <span class=\"label\"> 18. </span> <cite> Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643\u201355. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/jnci/dji112\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/15870435/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=Epidermal%20growth%20factor%20receptor%20gene%20and%20protein%20and%20gefitinib%20sensitivity%20in%20non-small-cell%20lung%20cancer&amp;author=F%20Cappuzzo&amp;author=FR%20Hirsch&amp;author=E%20Rossi&amp;author=S%20Bartolini&amp;author=GL%20Ceresoli&amp;volume=97&amp;publication_year=2005&amp;pages=643-55&amp;pmid=15870435&amp;doi=10.1093/jnci/dji112&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref019\"> <span class=\"label\"> 19. </span> <cite> Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, et al. Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist. 2015;20:316\u201322. 10.1634/theoncologist.2014-0389 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1634/theoncologist.2014-0389\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4350802/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25721120/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Fluorescence%20In%20Situ%20Hybridization,%20Immunohistochemistry,%20and%20Next-Generation%20Sequencing%20for%20Detection%20of%20EML4-ALK%20Rearrangement%20in%20Lung%20Cancer&amp;author=M%20Pekar-Zlotin&amp;author=FR%20Hirsch&amp;author=L%20Soussan-Gutman&amp;author=M%20Ilouze&amp;author=A%20Dvir&amp;volume=20&amp;publication_year=2015&amp;pages=316-22&amp;pmid=25721120&amp;doi=10.1634/theoncologist.2014-0389&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref020\"> <span class=\"label\"> 20. </span> <cite> Ali S, Ou SH, He J, Peled N, Chmielecki J, Pinder MC, et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. J Clin Oncol. 2014;32:5s. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Identifying%20ALK%20rearrangements%20that%20are%20not%20detected%20by%20FISH%20with%20targeted%20next-generation%20sequencing%20of%20lung%20carcinoma&amp;author=S%20Ali&amp;author=SH%20Ou&amp;author=J%20He&amp;author=N%20Peled&amp;author=J%20Chmielecki&amp;volume=32&amp;publication_year=2014&amp;pages=5s&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref021\"> <span class=\"label\"> 21. </span> <cite> Olga Anczuk\u00f3w, Avi Z Rosenberg, Martin Akerman, Shipra Das, Lixing Zhan, Rotem Karni, Senthil K Muthuswamy, Adrian R Krainer, The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nature Structural &amp; Molecular Biology 19, 2012; 220\u2013228 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nsmb.2207\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3272117/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22245967/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature%20Structural%20&amp;%20Molecular%20Biology&amp;title=The%20splicing%20factor%20SRSF1%20regulates%20apoptosis%20and%20proliferation%20to%20promote%20mammary%20epithelial%20cell%20transformation&amp;author=Anczuk%C3%B3w%20Olga&amp;author=Z%20Rosenberg%20Avi&amp;author=Akerman%20Martin&amp;author=Das%20Shipra&amp;author=Zhan%20Lixing&amp;volume=19&amp;publication_year=2012&amp;pages=220-228&amp;pmid=22245967&amp;doi=10.1038/nsmb.2207&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref022\"> <span class=\"label\"> 22. </span> <cite> Hannah L. Gautrey, Alison J. Tyson-Capper, Regulation of Mcl-1 by SRSF1 and SRSF5 in Cancer Cells. 2012; PLoS ONE 7(12): e51497 10.1371/journal.pone.0051497 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0051497\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3524227/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23284704/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Tyson-Capper,%20Regulation%20of%20Mcl-1%20by%20SRSF1%20and%20SRSF5%20in%20Cancer%20Cells&amp;author=L%20Hannah&amp;author=%20Gautrey&amp;author=J%20Alison&amp;volume=7&amp;issue=12&amp;publication_year=2012&amp;pages=e51497&amp;pmid=23284704&amp;doi=10.1371/journal.pone.0051497&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref023\"> <span class=\"label\"> 23. </span> <cite> Sedelnikova OA, Rogakou EP, Panuytin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res. 2002; 158:486\u201349. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1667/0033-7587(2002)158%5B0486:qdoiid%5D2.0.co;2\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/12236816/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Radiat%20Res&amp;title=Quantitative%20detection%20of%20(125)IdU-induced%20DNA%20double-strand%20breaks%20with%20gamma-H2AX%20antibody&amp;author=OA%20Sedelnikova&amp;author=EP%20Rogakou&amp;author=IG%20Panuytin&amp;author=WM%20Bonner&amp;volume=158&amp;publication_year=2002&amp;pages=486-49&amp;pmid=12236816&amp;doi=10.1667/0033-7587(2002)158%5B0486:qdoiid%5D2.0.co;2&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref024\"> <span class=\"label\"> 24. </span> <cite> Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol. 2003;5:4465\u20134479. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ncb974\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/12717439/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Cell%20Biol&amp;title=Chk2%20activates%20E2F-1%20in%20response%20to%20DNA%20damage&amp;author=C%20Stevens&amp;author=L%20Smith&amp;author=NB%20La%20Thangue&amp;volume=5&amp;publication_year=2003&amp;pages=4465-4479&amp;pmid=12717439&amp;doi=10.1038/ncb974&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref025\"> <span class=\"label\"> 25. </span> <cite> Ahn JW, Kim HS, Yoon JK, Jang H, Han SM, Eun S, et al. Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. Genome Med. 2014; 6(2):18 10.1186/gm535 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/gm535\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3979047/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24576404/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Med&amp;title=Identification%20of%20somatic%20mutations%20in%20EGFR/KRAS/ALK-negative%20lung%20adenocarcinoma%20in%20never-smokers&amp;author=JW%20Ahn&amp;author=HS%20Kim&amp;author=JK%20Yoon&amp;author=H%20Jang&amp;author=SM%20Han&amp;volume=6&amp;issue=2&amp;publication_year=2014&amp;pages=18&amp;pmid=24576404&amp;doi=10.1186/gm535&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref026\"> <span class=\"label\"> 26. </span> <cite> Yu J, Wu WK, Li X, He J, Li XX, Ng SS, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2015; 64(4):636\u20134. 10.1136/gutjnl-2013-306620 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1136/gutjnl-2013-306620\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4392212/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24951259/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Novel%20recurrently%20mutated%20genes%20and%20a%20prognostic%20mutation%20signature%20in%20colorectal%20cancer&amp;author=J%20Yu&amp;author=WK%20Wu&amp;author=X%20Li&amp;author=J%20He&amp;author=XX%20Li&amp;volume=64&amp;issue=4&amp;publication_year=2015&amp;pages=636-4&amp;pmid=24951259&amp;doi=10.1136/gutjnl-2013-306620&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref027\"> <span class=\"label\"> 27. </span> <cite> Swan MK, Johnson RE, Prakash L, Prakash S, Aggarwal AK. Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase delta. Nat Struct Mol Biol. 2009; 9:979\u201386. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nsmb.1663\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3055789/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19718023/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Struct%20Mol%20Biol&amp;title=Structural%20basis%20of%20high-fidelity%20DNA%20synthesis%20by%20yeast%20DNA%20polymerase%20delta&amp;author=MK%20Swan&amp;author=RE%20Johnson&amp;author=L%20Prakash&amp;author=S%20Prakash&amp;author=AK%20Aggarwal&amp;volume=9&amp;publication_year=2009&amp;pages=979-86&amp;pmid=19718023&amp;doi=10.1038/nsmb.1663&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref028\"> <span class=\"label\"> 28. </span> <cite> Auerbach AD. A test for Fanconi\u2019s anemia. Blood. 1988; 72: 366\u2013367. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/3291985/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20test%20for%20Fanconi%E2%80%99s%20anemia&amp;author=AD%20Auerbach&amp;volume=72&amp;publication_year=1988&amp;pages=366-367&amp;pmid=3291985&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref029\"> <span class=\"label\"> 29. </span> <cite> Owe S. W, Ruley H. E, Jacks T, Housman E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74: 957\u2013967. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/0092-8674(93)90719-7\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/8402885/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=p53-dependent%20apoptosis%20modulates%20the%20cytotoxicity%20of%20anticancer%20agents&amp;author=S.%20W%20Owe&amp;author=H.%20E%20Ruley&amp;author=T%20Jacks&amp;author=E%20Housman&amp;volume=74&amp;publication_year=1993&amp;pages=957-967&amp;pmid=8402885&amp;doi=10.1016/0092-8674(93)90719-7&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref030\"> <span class=\"label\"> 30. </span> <cite> Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 1996;50:1536\u20131540. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/8967975/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol.%20Pharmacol&amp;title=Cisplatin,%20camptothecin,%20and%20Taxol%20sensitivities%20of%20cells%20with%20p53-associated%20multidrug%20resistance&amp;author=PA%20Vasey&amp;author=NA%20Jones&amp;author=S%20Jenkins&amp;author=C%20Dive&amp;author=R%20Brown&amp;volume=50&amp;publication_year=1996&amp;pages=1536-1540&amp;pmid=8967975&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref031\"> <span class=\"label\"> 31. </span> <cite> Vikhanskaya F, Clerico L, Valenti M, Stanzione M. S, Broggini M, Parodi S, et al. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int. J. Cancer. 1997;72: 155\u2013159. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/(sici)1097-0215(19970703)72:1&lt;155::aid-ijc22&gt;3.0.co;2-h\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/9212237/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Cancer&amp;title=Mechanism%20of%20resistance%20to%20cisplatin%20in%20a%20human%20ovarian-carcinoma%20cell%20line%20selected%20for%20resistance%20to%20doxorubicin:%20possible%20role%20of%20p53&amp;author=F%20Vikhanskaya&amp;author=L%20Clerico&amp;author=M%20Valenti&amp;author=M.%20S%20Stanzione&amp;author=M%20Broggini&amp;volume=72&amp;publication_year=1997&amp;pages=155-159&amp;pmid=9212237&amp;doi=10.1002/(sici)1097-0215(19970703)72:1&lt;155::aid-ijc22&gt;3.0.co;2-h&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref032\"> <span class=\"label\"> 32. </span> <cite> Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther. 2006;5:1239\u201347. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1535-7163.MCT-05-0491\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/16731756/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&amp;title=DNA%20mismatch%20repair%20and%20p53%20function%20are%20major%20determinants%20of%20the%20rate%20of%20development%20of%20cisplatin%20resistance&amp;author=X%20Lin&amp;author=SB%20Howell&amp;volume=5&amp;publication_year=2006&amp;pages=1239-47&amp;pmid=16731756&amp;doi=10.1158/1535-7163.MCT-05-0491&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref033\"> <span class=\"label\"> 33. </span> <cite> Ishikawa T, Krzysko KA, Kowalska-Loth B, Skrajna AM, Czubaty A, Girstun A, Cieplak MK, Lesyng B, Staron K. Activities of topoisomerase I in its complex with SRSF1. Biochemistry. 2012. 51(8):1803\u201316 10.1021/bi300043t </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/bi300043t\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22320324/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Activities%20of%20topoisomerase%20I%20in%20its%20complex%20with%20SRSF1&amp;author=T%20Ishikawa&amp;author=KA%20Krzysko&amp;author=B%20Kowalska-Loth&amp;author=AM%20Skrajna&amp;author=A%20Czubaty&amp;volume=51&amp;issue=8&amp;publication_year=2012&amp;pages=1803-16&amp;pmid=22320324&amp;doi=10.1021/bi300043t&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref034\"> <span class=\"label\"> 34. </span> <cite> Pillai RN, Owonikoko TK. Small Cell Lung Cancer: Therapies and Targets. Semin Oncol. 2014; 41:133\u2013142. 10.1053/j.seminoncol.2013.12.015 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1053/j.seminoncol.2013.12.015\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4176613/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24565587/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Semin%20Oncol&amp;title=Small%20Cell%20Lung%20Cancer:%20Therapies%20and%20Targets&amp;author=RN%20Pillai&amp;author=TK%20Owonikoko&amp;volume=41&amp;publication_year=2014&amp;pages=133-142&amp;pmid=24565587&amp;doi=10.1053/j.seminoncol.2013.12.015&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref035\"> <span class=\"label\"> 35. </span> <cite> Tuduri S, Crabb\u00e9 L, Conti C, Tourri\u00e8re H, Holtgreve-Grez H, Jauch A, Pantesco V, De Vos J, Thomas A, Theillet C, Pommier Y, Tazi J, Coquelle A, Pasero P. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol. 2009;11(11):1315\u201324. 10.1038/ncb1984 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ncb1984\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2912930/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19838172/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Cell%20Biol&amp;title=Topoisomerase%20I%20suppresses%20genomic%20instability%20by%20preventing%20interference%20between%20replication%20and%20transcription&amp;author=S%20Tuduri&amp;author=L%20Crabb%C3%A9&amp;author=C%20Conti&amp;author=H%20Tourri%C3%A8re&amp;author=H%20Holtgreve-Grez&amp;volume=11&amp;issue=11&amp;publication_year=2009&amp;pages=1315-24&amp;pmid=19838172&amp;doi=10.1038/ncb1984&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref036\"> <span class=\"label\"> 36. </span> <cite> Das S, Anczuk\u00f3w O, Akerman M, Krainer AR, Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. 2012; Cell Rep. 110\u20137 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.celrep.2011.12.001\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3334311/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22545246/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=Oncogenic%20splicing%20factor%20SRSF1%20is%20a%20critical%20transcriptional%20target%20of%20MYC&amp;author=S%20Das&amp;author=O%20Anczuk%C3%B3w&amp;author=M%20Akerman&amp;author=AR%20Krainer&amp;publication_year=2012&amp;pages=110-7&amp;pmid=22545246&amp;doi=10.1016/j.celrep.2011.12.001&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref037\"> <span class=\"label\"> 37. </span> <cite> Karni R., De Stanchina E., Lowe S. W., Sinha R., Mu D., Krainer A. R.. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology. 2007; 14(3):185\u2013193. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nsmb1209\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4595851/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17310252/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature%20Structural%20and%20Molecular%20Biology&amp;title=The%20gene%20encoding%20the%20splicing%20factor%20SF2/ASF%20is%20a%20proto-oncogene.&amp;author=R.%20Karni&amp;author=E.%20De%20Stanchina&amp;author=S.%20W.%20Lowe&amp;author=R.%20Sinha&amp;author=D.%20Mu&amp;volume=14&amp;issue=3&amp;publication_year=2007&amp;pages=185-193&amp;pmid=17310252&amp;doi=10.1038/nsmb1209&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref038\"> <span class=\"label\"> 38. </span> <cite> Anczuk\u00f3w O1, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19(2):220\u2013228. 10.1038/nsmb.2207 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nsmb.2207\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3272117/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22245967/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Struct%20Mol%20Biol&amp;title=The%20splicing%20factor%20SRSF1%20regulates%20apoptosis%20and%20proliferation%20to%20promote%20mammary%20epithelial%20cell%20transformation.&amp;author=O1%20Anczuk%C3%B3w&amp;author=AZ%20Rosenberg&amp;author=M%20Akerman&amp;author=S%20Das&amp;author=L%20Zhan&amp;volume=19&amp;issue=2&amp;publication_year=2012&amp;pages=220-228&amp;pmid=22245967&amp;doi=10.1038/nsmb.2207&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref039\"> <span class=\"label\"> 39. </span> <cite> Shimoni-Sebag A, Lebenthal-Loinger I, Zender L, Karni R. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. Carcinogenesis. 2013;34:2498\u2013504. 10.1093/carcin/bgt247 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/carcin/bgt247\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23843040/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Carcinogenesis&amp;title=RRM1%20domain%20of%20the%20splicing%20oncoprotein%20SRSF1%20is%20required%20for%20MEK1-MAPK-ERK%20activation%20and%20cellular%20transformation&amp;author=A%20Shimoni-Sebag&amp;author=I%20Lebenthal-Loinger&amp;author=L%20Zender&amp;author=R%20Karni&amp;volume=34&amp;publication_year=2013&amp;pages=2498-504&amp;pmid=23843040&amp;doi=10.1093/carcin/bgt247&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref040\"> <span class=\"label\"> 40. </span> <cite> Das S, Krainer AR. Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol Cancer Res. 2014;12:1195\u2013204. 10.1158/1541-7786.MCR-14-0131 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1541-7786.MCR-14-0131\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4163531/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24807918/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Res&amp;title=Emerging%20functions%20of%20SRSF1,%20splicing%20factor%20and%20oncoprotein,%20in%20RNA%20metabolism%20and%20cancer&amp;author=S%20Das&amp;author=AR%20Krainer&amp;volume=12&amp;publication_year=2014&amp;pages=1195-204&amp;pmid=24807918&amp;doi=10.1158/1541-7786.MCR-14-0131&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref041\"> <span class=\"label\"> 41. </span> <cite> Nicholas A. Olshavsky, Clay E.S. Comstock, Matthew J. Schiewer, Michael A. Augello, Terry Hyslop, Claudio Sette, et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res. 2010; 70(10):3975\u20133984. 10.1158/0008-5472.CAN-09-3468 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/0008-5472.CAN-09-3468\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2873684/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20460515/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Identification%20of%20ASF/SF2%20as%20a%20critical,%20allele-specific%20effector%20of%20the%20cyclin%20D1b%20oncogene&amp;author=A.%20Olshavsky%20Nicholas&amp;author=E.S.%20Comstock%20Clay&amp;author=%20Matthew%20J.%20Schiewer&amp;author=A.%20Augello%20Michael&amp;author=Hyslop%20Terry&amp;volume=70&amp;issue=10&amp;publication_year=2010&amp;pages=3975-3984&amp;pmid=20460515&amp;doi=10.1158/0008-5472.CAN-09-3468&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref042\"> <span class=\"label\"> 42. </span> <cite> Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer AR, Davidson B, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013;3:103\u201315. 10.1016/j.celrep.2012.11.020 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.celrep.2012.11.020\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5021319/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23273915/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=S6K1%20alternative%20splicing%20modulates%20its%20oncogenic%20activity%20and%20regulates%20mTORC1.&amp;author=V%20Ben-Hur&amp;author=P%20Denichenko&amp;author=Z%20Siegfried&amp;author=A%20Maimon&amp;author=AR%20Krainer&amp;volume=3&amp;publication_year=2013&amp;pages=103-15&amp;pmid=23273915&amp;doi=10.1016/j.celrep.2012.11.020&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref043\"> <span class=\"label\"> 43. </span> <cite> Ge H, Manley JL. A protein factor, ASF, controls cell-specific alternative splicing of SV40 early pre-mRNA in vitro. Cell. 1990; 62:25\u201334. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/0092-8674(90)90236-8\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/2163768/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=A%20protein%20factor,%20ASF,%20controls%20cell-specific%20alternative%20splicing%20of%20SV40%20early%20pre-mRNA%20in%20vitro&amp;author=H%20Ge&amp;author=JL%20Manley&amp;volume=62&amp;publication_year=1990&amp;pages=25-34&amp;pmid=2163768&amp;doi=10.1016/0092-8674(90)90236-8&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref044\"> <span class=\"label\"> 44. </span> <cite> Guo G, Sun X, Chen C, Wu S, Huang P, Li Z et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013; 45(12):1459\u201363. 10.1038/ng.2798 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ng.2798\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7512009/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24121792/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Whole-genome%20and%20whole-exome%20sequencing%20of%20bladder%20cancer%20identifies%20frequent%20alterations%20in%20genes%20involved%20in%20sister%20chromatid%20cohesion%20and%20segregation&amp;author=G%20Guo&amp;author=X%20Sun&amp;author=C%20Chen&amp;author=S%20Wu&amp;author=P%20Huang&amp;volume=45&amp;issue=12&amp;publication_year=2013&amp;pages=1459-63&amp;pmid=24121792&amp;doi=10.1038/ng.2798&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref045\"> <span class=\"label\"> 45. </span> <cite> McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303. 10.1101/gr.107524.110 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1101/gr.107524.110\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2928508/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20644199/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Res&amp;title=The%20Genome%20Analysis%20Toolkit:%20a%20MapReduce%20framework%20for%20analyzing%20next-generation%20DNA%20sequencing%20data&amp;author=A%20McKenna&amp;author=M%20Hanna&amp;author=E%20Banks&amp;author=A%20Sivachenko&amp;author=K%20Cibulskis&amp;volume=20&amp;issue=9&amp;publication_year=2010&amp;pages=1297-303&amp;pmid=20644199&amp;doi=10.1101/gr.107524.110&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref046\"> <span class=\"label\"> 46. </span> <cite> DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics. 2011;43:491\u2013498. 10.1038/ng.806 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ng.806\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3083463/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21478889/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature%20Genetics&amp;title=A%20framework%20for%20variation%20discovery%20and%20genotyping%20using%20next-generation%20DNA%20sequencing%20data&amp;author=M%20DePristo&amp;author=E%20Banks&amp;author=R%20Poplin&amp;author=K%20Garimella&amp;author=J%20Maguire&amp;volume=43&amp;publication_year=2011&amp;pages=491-498&amp;pmid=21478889&amp;doi=10.1038/ng.806&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref047\"> <span class=\"label\"> 47. </span> <cite> Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnology. 2013;31: 213\u2013219. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nbt.2514\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3833702/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23396013/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Biotechnology&amp;title=Sensitive%20detection%20of%20somatic%20point%20mutations%20in%20impure%20and%20heterogeneous%20cancer%20samples&amp;author=K%20Cibulskis&amp;author=MS%20Lawrence&amp;author=SL%20Carter&amp;author=A%20Sivachenko&amp;author=D%20Jaffe&amp;volume=31&amp;publication_year=2013&amp;pages=213-219&amp;pmid=23396013&amp;doi=10.1038/nbt.2514&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref048\"> <span class=\"label\"> 48. </span> <cite> Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. 1000 Genome Project Data Processing Subgroup The Sequence alignment/map (SAM) format and SAMtools. Bioinformatics. 2009; 25, 2078\u20139. 10.1093/bioinformatics/btp352 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/bioinformatics/btp352\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2723002/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19505943/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=1000%20Genome%20Project%20Data%20Processing%20Subgroup%20The%20Sequence%20alignment/map%20(SAM)%20format%20and%20SAMtools&amp;author=H%20Li&amp;author=B%20Handsaker&amp;author=A%20Wysoker&amp;author=T%20Fennell&amp;author=J%20Ruan&amp;volume=25&amp;publication_year=2009&amp;pages=2078-9&amp;pmid=19505943&amp;doi=10.1093/bioinformatics/btp352&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref049\"> <span class=\"label\"> 49. </span> <cite> Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499 (7457):214\u2013218. 10.1038/nature12213 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature12213\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3919509/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23770567/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Mutational%20heterogeneity%20in%20cancer%20and%20the%20search%20for%20new%20cancer-associated%20genes&amp;author=MS%20Lawrence&amp;author=P%20Stojanov&amp;author=P%20Polak&amp;author=GV%20Kryukov&amp;author=K%20Cibulskis&amp;volume=499&amp;issue=7457&amp;publication_year=2013&amp;pages=214-218&amp;pmid=23770567&amp;doi=10.1038/nature12213&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref050\"> <span class=\"label\"> 50. </span> <cite> Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011;108(41):17087\u201392. 10.1073/pnas.1108745108 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1073/pnas.1108745108\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3193229/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21949389/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Exome%20sequencing%20identifies%20a%20spectrum%20of%20mutation%20frequencies%20in%20advanced%20and%20lethal%20prostate%20cancers&amp;author=A%20Kumar&amp;author=TA%20White&amp;author=AP%20MacKenzie&amp;author=N%20Clegg&amp;author=C%20Lee&amp;volume=108&amp;issue=41&amp;publication_year=2011&amp;pages=17087-92&amp;pmid=21949389&amp;doi=10.1073/pnas.1108745108&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref051\"> <span class=\"label\"> 51. </span> <cite> Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from next-generation sequencing data Nucleic Acids Research. 2010; 38:e164. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkq603\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2938201/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20601685/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?Wang%20K,%20Li%20M,%20Hakonarson%20H.%20ANNOVAR:%20Functional%20annotation%20of%20genetic%20variants%20from%20next-generation%20sequencing%20data%20Nucleic%20Acids%20Research.%202010;%2038:e164.\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref052\"> <span class=\"label\"> 52. </span> <cite> Youn A, Simon R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics. 2011;27(2):175\u20138. 10.1093/bioinformatics/btq630 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/bioinformatics/btq630\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3018819/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21169372/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Identifying%20cancer%20driver%20genes%20in%20tumor%20genome%20sequencing%20studies&amp;author=A%20Youn&amp;author=R%20Simon&amp;volume=27&amp;issue=2&amp;publication_year=2011&amp;pages=175-8&amp;pmid=21169372&amp;doi=10.1093/bioinformatics/btq630&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref053\"> <span class=\"label\"> 53. </span> <cite> Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235\u201342. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/28.1.235\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC102472/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/10592235/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=The%20Protein%20Data%20Bank&amp;author=HM%20Berman&amp;author=J%20Westbrook&amp;author=Z%20Feng&amp;author=G%20Gilliland&amp;author=TN%20Bhat&amp;volume=28&amp;issue=1&amp;publication_year=2000&amp;pages=235-42&amp;pmid=10592235&amp;doi=10.1093/nar/28.1.235&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref054\"> <span class=\"label\"> 54. </span> <cite> Lee YS, Kennedy WD, Yin YW. Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell. 2009;139(2):312\u201324. 10.1016/j.cell.2009.07.050 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cell.2009.07.050\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3018533/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19837034/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Structural%20insight%20into%20processive%20human%20mitochondrial%20DNA%20synthesis%20and%20disease-related%20polymerase%20mutations&amp;author=YS%20Lee&amp;author=WD%20Kennedy&amp;author=YW%20Yin&amp;volume=139&amp;issue=2&amp;publication_year=2009&amp;pages=312-24&amp;pmid=19837034&amp;doi=10.1016/j.cell.2009.07.050&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref055\"> <span class=\"label\"> 55. </span> <cite> Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36 10.1186/gb-2013-14-4-r36 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/gb-2013-14-4-r36\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4053844/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23618408/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Biol&amp;title=TopHat2:%20accurate%20alignment%20of%20transcriptomes%20in%20the%20presence%20of%20insertions,%20deletions%20and%20gene%20fusions&amp;author=D%20Kim&amp;author=G%20Pertea&amp;author=C%20Trapnell&amp;author=H%20Pimentel&amp;author=R%20Kelley&amp;volume=14&amp;issue=4&amp;publication_year=2013&amp;pages=R36&amp;pmid=23618408&amp;doi=10.1186/gb-2013-14-4-r36&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref056\"> <span class=\"label\"> 56. </span> <cite> Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357\u2013359. 10.1038/nmeth.1923 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nmeth.1923\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3322381/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22388286/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Methods&amp;title=Fast%20gapped-read%20alignment%20with%20Bowtie%202&amp;author=B%20Langmead&amp;author=SL%20Salzberg&amp;volume=9&amp;issue=4&amp;publication_year=2012&amp;pages=357-359&amp;pmid=22388286&amp;doi=10.1038/nmeth.1923&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref057\"> <span class=\"label\"> 57. </span> <cite> Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biology. 2010;11(10):R106 10.1186/gb-2010-11-10-r106 </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/gb-2010-11-10-r106\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3218662/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20979621/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Biology&amp;title=Differential%20expression%20analysis%20for%20sequence%20count%20data&amp;author=S%20Anders&amp;author=W%20Huber&amp;volume=11&amp;issue=10&amp;publication_year=2010&amp;pages=R106&amp;pmid=20979621&amp;doi=10.1186/gb-2010-11-10-r106&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"pgen.1005895.ref058\"> <span class=\"label\"> 58. </span> <cite> Sathirapongsasuti JF, Lee H, Horst BA, Brunner G, Cochran AJ, Binder S, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011;19:2648\u201354. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/bioinformatics/btr462\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3179661/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21828086/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Exome%20sequencing-based%20copy-number%20variation%20and%20loss%20of%20heterozygosity%20detection:%20ExomeCNV&amp;author=JF%20Sathirapongsasuti&amp;author=H%20Lee&amp;author=BA%20Horst&amp;author=G%20Brunner&amp;author=AJ%20Cochran&amp;volume=19&amp;publication_year=2011&amp;pages=2648-54&amp;pmid=21828086&amp;doi=10.1093/bioinformatics/btr462&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> </ul> </section> </section> <section class=\"associated-data\" id=\"_ad93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ad93_-anchor\"> </a> Associated Data </h2> <p class=\"font-secondary\"> <em> This section collects any data citations, data availability statements, or supplementary materials included in this article. </em> </p> <section class=\"supplementary-materials\" id=\"_adsm93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Supplementary Materials </h3> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material1_reqid_\"> <div class=\"caption p\"> <span> S1 Fig. Genomic alterations in Chinese SCLC patients. </span> <p> Tumor samples (n = 99) are ordered from left to right based on SRSF1 copy number gains. Mutations and DNA copy number alterations of key SCLC oncogenic genes are indicated for each sample according to the color legend below the figure. The genomic alteration frequencies for each candidate gene are displayed on the left. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s001.docx\"> Click here for additional data file. </a> <sup> (72.4KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material2_reqid_\"> <div class=\"caption p\"> <span> S2 Fig. SRSF1 gene copy number detection by FISH. </span> <p> Representative images show a) SRSF1 normal and b) SRSF1 copy number gain. Red signals represent SRSF1 gene and green signals represent of CEP17; c) SRSF1 CNV SCLC patient prevalence as well as other CNV segments across chromosome 17. Red lines indicate CN gains and green lines indicate CN losses. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s002.docx\"> Click here for additional data file. </a> <sup> (3.1MB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material3_reqid_\"> <div class=\"caption p\"> <span> S3 Fig. KM curves from indications in TCGA where at least 3 patients harbored a CN gain of SRSF1. </span> <p> Plots were generated in OncoLand (OmicSoft Corp; Cary, NC). </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s003.docx\"> Click here for additional data file. </a> <sup> (111.5KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material4_reqid_\"> <div class=\"caption p\"> <span> S4 Fig </span> <p> (a): TaqMan assays of SRSF1 DNA CNs in 13 SCLC cell lines. (b): Western blots of SRSF1 show protein expression levels in SCLC cell lines. (c):NCI-H82, SHP-77 and NCI-H1048 were transfected with non-targeting control or SRSF1-directed siRNAs for 48 hrs, then treated with cisplatin (2.5ug/ml) or topotecan (2.5ug/ml) for 24 hrs. Cell growth and Caspase-3/7 activities were assessed and normalized against ctrl siRNA-transfected cells as 100% control. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s004.docx\"> Click here for additional data file. </a> <sup> (214.4KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material5_reqid_\"> <div class=\"caption p\"> <span> S5 Fig. The association of SRSF1 gene expression with BIM gene expression in Chinese SCLC patients (N = 49). </span> <p> The correlation between SRSF1 and BIM gene expression is significant, which likely confirms SRSF1 over expression promotes alternative splicing of BIM. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s005.docx\"> Click here for additional data file. </a> <sup> (100.2KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material6_reqid_\"> <div class=\"caption p\"> <span> S6 Fig. NCI-82, SHP-77 and NIH-H1048 cells were transfected with non-targeting and SRSF1 siRNAs respectively for 48 hrs and then seeded in sphere forming media and allowed to grow for 4 days. </span> <p> (a): Phase-contrast images of the sphere formation under each condition were captured. (b): viable cell mass quantitated by CTG assay. (c): Reconstitution of SRSF1 expression using a siRNA-resistant Flag-tagged SRSF1 expression construct was carried out in SRSF1 siRNA transfected NCI-H82 cells. Impact on sphere growth rate was assessed by CTG assay, and successful SRSF1 protein re-expression was confirmed by WB using either anti-SRSF1 antibody or anti-Flag antibody. (d): Clonogenic assays of DMS-114, NCI-82, SHP-77 and NIH-H1049. Cells were transfected with siRNAs for 48 hrs and then seeded in the methylcellulose medium for 7~14 days, colonies with more than 40 cells per colony were counted. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s006.docx\"> Click here for additional data file. </a> <sup> (193.2KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material7_reqid_\"> <div class=\"caption p\"> <span> S7 Fig </span> <p> (a)SHP-77 cells transfected with non-targeting control siRNA or SRSF1 siRNA were implanted into immunocompromised mice and tumor formation rates were monitored and measured. (b): SHP-77 cells were transfected with control or SRSF1 siRNA and then treated with topotecan or Cisplatin for the indicated times. SRSF1, phosphor-H2AX and phosphor-Chk2 were probed with their corresponding antibodies. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s007.docx\"> Click here for additional data file. </a> <sup> (135.6KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material8_reqid_\"> <div class=\"caption p\"> <span> S8 Fig. The association of SRSF1 gene expression with early stage and late stage (ES) SCLC patients in both our Chinese SCLC study (left figure) and George et al, study (right figure). </span> <p> P-value is calculated using Welch\u2019s modified t-test. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s008.docx\"> Click here for additional data file. </a> <sup> (125.6KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material9_reqid_\"> <div class=\"caption p\"> <span> S9 Fig. The association of SRSF1 gene expression with MYC CNV status. </span> <p> SCLC cell lines (left figure, N = 11) and our Chinese SCLC study (right figure, N = 49 patients with matched expression and CNV samples). P-value is estimated using standard t-test. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s009.docx\"> Click here for additional data file. </a> <sup> (125KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material10_reqid_\"> <div class=\"caption p\"> <span> S10 Fig. Identity check between matched SCLC tumor and normal specimens. </span> <p> Pearson correlation heatmap is used to compare 300 germline SNP profiles between each of the 25 tumors and matched normals. Gradient of colors: green = no correlation; yellow = low correlation; white = high correlation. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s010.docx\"> Click here for additional data file. </a> <sup> (113.5KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material11_reqid_\"> <div class=\"caption p\"> <span> S11 Fig. Tumor growth curves for DMS114 and SHP77 parental cell lines. </span> <p> A total of 5\u201310 millioins cells were injected to establish xenograft tumors. </p> <p> (DOCX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s011.docx\"> Click here for additional data file. </a> <sup> (79.9KB, docx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material12_reqid_\"> <div class=\"caption p\"> <span> S1 Table. Chinese patient clinical summary (n = 99). </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s012.xlsx\"> Click here for additional data file. </a> <sup> (21.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material13_reqid_\"> <div class=\"caption p\"> <span> S2 Table. Recurrent somatic mutated genes from 99 Chinese SCLC patients; additional recurrent rates from 51 SCLC Japanese patients in an independent study [ <a aria-describedby=\"pgen.1005895.ref005\" aria-expanded=\"false\" class=\"usa-link\" href=\"#pgen.1005895.ref005\"> 5 </a> ]. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s013.xlsx\"> Click here for additional data file. </a> <sup> (93.1KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material14_reqid_\"> <div class=\"caption p\"> <span> S3 Table. Cancer driver gene intersection by two methods and two public data sets in 99 Chinese SCLC. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s014.xlsx\"> Click here for additional data file. </a> <sup> (21.3KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material15_reqid_\"> <div class=\"caption p\"> <span> S4 Table. SNVs within DNA repair mechanisms in Chinese SCLC patients (n = 99) using nonsilent somatic SNVs and indels. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s015.xlsx\"> Click here for additional data file. </a> <sup> (64.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material16_reqid_\"> <div class=\"caption p\"> <span> S5 Table. Patient counts harboring recurrent (prevalence&gt;20%) gene-level somatic CNVs in discovery and validation cohorts (n = 96). </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s016.xlsx\"> Click here for additional data file. </a> <sup> (284.7KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material17_reqid_\"> <div class=\"caption p\"> <span> S6 Table. FISH assay confirmation of WES CN calls for SRSF1. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s017.xlsx\"> Click here for additional data file. </a> <sup> (16.2KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material18_reqid_\"> <div class=\"caption p\"> <span> S7 Table </span> <p> A. Kaplan-Meier analysis summary for SRSF1 DNA amplification and mRNA expression; B. Cox proportion hazard regression analysis summary for SRSF1 DNA amplification and mRNA over-expression. </p> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s018.xlsx\"> Click here for additional data file. </a> <sup> (17KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material19_reqid_\"> <div class=\"caption p\"> <span> S8 Table. Patient-specific somatic nonsilent SNVs/indels from 99 Chinese SCLC patients. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s019.xlsx\"> Click here for additional data file. </a> <sup> (3.9MB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material20_reqid_\"> <div class=\"caption p\"> <span> S9 Table. Gene expression (RNASeq) of top up/down regulated genes between 48 tumor and 6 normal samples. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s020.xlsx\"> Click here for additional data file. </a> <sup> (160.9KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material21_reqid_\"> <div class=\"caption p\"> <span> S10 Table. WES coverage and depth statistics for 99 tumor specimens. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s021.xlsx\"> Click here for additional data file. </a> <sup> (21.9KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material22_reqid_\"> <div class=\"caption p\"> <span> S11 Table. Commercial Caucasian patient information. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s022.xlsx\"> Click here for additional data file. </a> <sup> (12.8KB, xlsx) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material23_reqid_\"> <div class=\"caption p\"> <span> S12 Table. Mater Regulator Analysis (Ingenuity Pathway Analysis) for differential expression genes between SRSF1 CN Gain / Amp and SRSF1 CN Neutral. </span> <p> (XLSX) </p> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/4836692/bin/pgen.1005895.s023.xlsx\"> Click here for additional data file. </a> <sup> (16KB, xlsx) </sup> </div> </div> </section> </section> <section class=\"data-availability-statement\" id=\"_adda93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Data Availability Statement </h3> <p> All analysis results are within the paper and its Supporting Information files. RNASeq data has been deposited into GEO under accession GSE60052 ( <a class=\"usa-link\" href=\"http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60052\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60052 </a> ); while WES data was deposited into dBGaP under accession ID phs001083.v1.p1 ( <a class=\"usa-link\" href=\"http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001083.v1.p1\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001083.v1.p1 </a> .) </p> </section> </section> </section> <footer class=\"p courtesy-note font-secondary font-sm text-center\"> <hr class=\"headless\"/> <p> Articles from PLoS Genetics are provided here courtesy of <strong> PLOS </strong> </p> </footer> </section> </article> </main> </div> </div> </div> <div class=\"pmc-sidenav desktop:grid-col-4 display-flex\"> <section aria-label=\"Article resources and navigation\" class=\"pmc-sidenav__container\"> <button class=\"usa-button pmc-sidenav__container__close usa-button--unstyled\" type=\"button\"> <img alt=\"Close\" role=\"img\" src=\"/static/img/usa-icons/close.svg\"/> </button> <div class=\"display-none desktop:display-block\"> <section class=\"margin-top-4 desktop:margin-top-0\"> <h2 class=\"margin-top-0\"> ACTIONS </h2> <ul class=\"usa-list usa-list--unstyled usa-list--actions\"> <li> <a class=\"usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"https://doi.org/10.1371/journal.pgen.1005895\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 padding-right-2\"> View on publisher site </span> </a> </li> <li> <a class=\"usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"pdf/pgen.1005895.pdf\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> PDF (3.0 MB) </span> </a> </li> <li> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1\" role=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Cite </span> </button> </li> <li> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> Collections </span> </button> </li> <li class=\"pmc-permalink\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Permalink </span> </button> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4836692/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class=\"pmc-resources margin-top-6 desktop:margin-top-4\"> <h2 class=\"margin-top-0\"> RESOURCES </h2> <div class=\"usa-accordion usa-accordion--multiselectable\"> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-similar-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Similar articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-similar-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-cited-by-other-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Cited by other articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-cited-by-other-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-links-to-ncbi-databases\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Links to NCBI Databases </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-links-to-ncbi-databases\"> </div> </div> </section> <section class=\"usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4\"> <nav aria-label=\"On this page\" class=\"usa-in-page-nav__nav\"> <h2 class=\"usa-in-page-nav__heading\" tabindex=\"0\"> On this page </h2> <ul class=\"usa-in-page-nav__list\"> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#abstract1\"> Abstract </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#abstract2\"> Author Summary </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec001\"> Introduction </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec002\"> Results </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec009\"> Discussion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec010\"> Methods </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec028\"> Supporting Information </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ack1\"> Acknowledgments </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#notes1\"> Data Availability </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#funding-statement1\"> Funding Statement </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ref-list1\"> References </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ad93_\"> Associated Data </a> </li> </ul> </nav> </section> </section> </div> <div aria-label=\"Citation Dialog\" class=\"overlay citation-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog citation-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Cite </h2> <button class=\"usa-button usa-button--unstyled close-overlay text-black width-auto\" tabindex=\"1\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"citation-text-block\"> <div class=\"citation-text margin-bottom-2\"> </div> <ul class=\"usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center\"> <li> <button class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus\" tabindex=\"2\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span> Copy </span> </button> </li> <li> <a class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button\" href=\"#\" role=\"button\" tabindex=\"3\" title=\"Download a file for external citation management software\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-none mobile-lg:display-inline\"> Download .nbib </span> <span class=\"display-inline mobile-lg:display-none\"> .nbib </span> </a> </li> <li> <div class=\"display-inline-flex flex-align-center\"> <label class=\"usa-label margin-top-0\"> Format: </label> <select aria-label=\"Format\" class=\"usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4\" tabindex=\"4\"> <option value=\"AMA\"> AMA </option> <option value=\"APA\"> APA </option> <option value=\"MLA\"> MLA </option> <option selected=\"selected\" value=\"NLM\"> NLM </option> </select> </div> </li> </ul> <div class=\"dots-loading-indicator citation-loading-indicator\"> <div class=\"dot dot-1\"> </div> <div class=\"dot dot-2\"> </div> <div class=\"dot dot-3\"> </div> </div> </div> </div> </div> <div class=\"overlay collections-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog collections-dialog\" id=\"collections-action-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Add to Collections </h2> </div> <div class=\"collections-action-panel action-panel\"> <form class=\"usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors\" id=\"collections-action-dialog-form\"> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"usa-radio\"> <input class=\"usa-radio__input usa-radio__input--tile collections-new margin-top-0\" id=\"collections-action-dialog-new\" name=\"collections\" type=\"radio\" value=\"new\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-new\"> Create a new collection </label> </div> <div class=\"usa-radio\"> <input checked=\"true\" class=\"usa-radio__input usa-radio__input--tile collections-existing\" id=\"collections-action-dialog-existing\" name=\"collections\" type=\"radio\" value=\"existing\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-existing\"> Add to an existing collection </label> </div> </fieldset> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"action-panel-control-wrap new-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-new\"> Name your collection <abbr class=\"usa-hint usa-hint--required text-no-underline\" title=\"required\"> * </abbr> </label> <input class=\"usa-input collections-action-add-to-new\" id=\"collections-action-dialog-add-to-new\" maxlength=\"\" name=\"add-to-new-collection\" pattern='[^\"&amp;=&lt;&gt;/]*' required=\"\" title='The following characters are not allowed in the Name field: \"&amp;=&lt;&gt;/' type=\"text\"/> </div> <div class=\"action-panel-control-wrap existing-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-existing\"> Choose a collection </label> <select class=\"usa-select collections-action-add-to-existing\" id=\"collections-action-dialog-add-to-existing\"> </select> <div class=\"collections-retry-load-on-error usa-input-error-message selection-validation-message\"> Unable to load your collection due to an error <br/> <a href=\"#\"> Please try again </a> </div> </div> </fieldset> <div class=\"display-inline-flex\"> <button class=\"usa-button margin-top-0 action-panel-submit\" type=\"submit\"> Add </button> <button aria-label=\"Close 'Add to Collections' panel\" class=\"usa-button usa-button--outline margin-top-0 action-panel-cancel\" ref=\"linksrc=close_collections_panel\"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class=\"ncbi-footer ncbi-dark-background\"> <div class=\"ncbi-footer__icon-section\"> <div class=\"ncbi-footer__social-header\"> Follow NCBI </div> <div class=\"grid-container ncbi-footer__ncbi-social-icons-container\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://twitter.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"40\" viewbox=\"0 0 40 40\" width=\"40\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.facebook.com/ncbi.nlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"29\" viewbox=\"0 0 16 29\" width=\"16\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.linkedin.com/company/ncbinlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"23\" viewbox=\"0 0 26 24\" width=\"25\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z\"> </path> <path d=\"M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z\"> </path> <path d=\"M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on LinkedIn </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://github.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"27\" viewbox=\"0 0 28 28\" width=\"28\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on GitHub </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://ncbiinsights.ncbi.nlm.nih.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"26\" viewbox=\"0 0 27 27\" width=\"26\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z\"> </path> <path d=\"M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z\"> </path> <path d=\"M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI RSS feed </span> </a> </div> </div> <div class=\"grid-container ncbi-footer__container\"> <div class=\"grid-row ncbi-footer__main-content-container\"> <div class=\"ncbi-footer__column\"> <p class=\"ncbi-footer__circled-icons-heading\"> Connect with NLM </p> <div class=\"ncbi-footer__circled-icons-list\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://twitter.com/nlm_nih\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"32\" viewbox=\"0 0 40 40\" width=\"32\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.facebook.com/nationallibraryofmedicine\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"24\" viewbox=\"0 0 13 24\" width=\"13\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.youtube.com/user/NLMNIH\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"15\" viewbox=\"0 0 21 15\" width=\"21\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z\" fill=\"white\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on YouTube </span> </a> </div> </div> <address class=\"ncbi-footer__address ncbi-footer__column\"> <p> <a class=\"usa-link usa-link--external\" href=\"https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323\" rel=\"noopener noreferrer\" target=\"_blank\"> National Library of Medicine <br/> 8600 Rockville Pike <br/> Bethesda, MD 20894 </a> </p> </address> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/web_policies.html\"> Web Policies </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office\"> FOIA </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/vulnerability-disclosure-policy/index.html\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS Vulnerability Disclosure </a> </li> </ul> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal\"> Help </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/accessibility.html\"> Accessibility </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/careers/careers.html\"> Careers </a> </li> </ul> </div> <div class=\"grid-row grid-col-12\"> <ul class=\"ncbi-footer__bottom-links-list\"> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/\"> NLM </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/\"> NIH </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.usa.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> USA.gov </a> </li> </ul> </div> </div> </footer> <div id=\"ZN_dikYWqsjiUWN0Q5\"> </div> <button class=\"back-to-top\"> <label> Back to Top </label> <svg aria-hidden=\"true\" class=\"usa-icon order-0\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#arrow_upward\"> </use> </svg> </button> <div class=\"fake-body-scroll\"> </div> <div class=\"fake-body-scroll\"> </div> <div class=\"QSIFeedbackButton\"> <button aria-label=\"Tell us what you think!\" id=\"QSIFeedbackButton-btn\" role=\"button\"> <img alt=\"Tell us what you think!\" src=\"https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S\"/> </button> </div> </body> </html>\n\nand the following known data repositories: bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov\n\nFor each dataset reference, return the following as a JSON array of objects. Each object must have:\n- `dataset_identifier`: The dataset identifier (which must be a code). If unavailable, set it to \"n/a\".\n- `repository_reference`: The URL or reference to the data repository. If unavailable, set it to \"n/a\".\n\nStrict Instructions:\n- Output must be a valid JSON array of objects.\n- Each object must contain `dataset_id` and `repository_reference`.\n- Any other output will be considered invalid."}]}]